Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase

ABSTRACT

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.

BACKGROUND OF THE INVENTION

. .This application is a continuation-in-part application of U.S. Ser.No. 07/988,515 filed Dec. 10, 1992, now abandoned which is acontinuation-in-part application of U.S. Ser. No. 07/698,420, filed May10, 1991 now abandoned and a continuation-in-part application of PCTInternational Application Ser. No. PCT/US92/03736 filed May 6, 1992..!.

.Iadd.This application is a reissue of 08/166,199, filed Dec. 10, 1993,now U.S. Pat. No. 5,480,883, which, in turn, is a continuation-in-partapplication of U.S. patent application Ser. No. 07/988,515, filed Dec.10, 1992, now abandoned, which, in turn, is a continuation-in-partapplication of International Patent Application No. PCT/US92/03736,filed May 6, 1992, now abandoned, which, in turn, is acontinuation-in-part application of U.S. patent application Ser. No.07/698,420, filed May 10, 1991, now abandoned. This application is alsoa reissue of 08/166,199, filed Dec. 10, 1993, now U.S. Pat. No.5,480,883, which, in turn, is a continuation-in-part of U.S. patentapplication Ser. No. 08/146,072, filed Nov. 8, 1993, now U.S. Pat. No.5,409,930, which is the National Stage of International PatentApplication No. PCT/US92/03736, filed May 6, 1992, now abandoned, which,in turn, is a continuation-in-part application of U.S. patentapplication Ser. No. 07/698,420, filed May 10, 1991, now abandoned..Iaddend.

FIELD OF THE INVENTION

This invention relates to the modulation and/or inhibition of cellsignaling, cell proliferation, cell inflammatory response, the controlof abnormal cell growth and cell reproduction. More specifically, thisinvention relates to the use of bis mono- and/or bicyclic aryl and/orheteroaryl compounds in inhibiting cell proliferation, includingcompounds which are useful protein tyrosine kinase (PTK) inhibitors.

Normal cellular reproduction is believed to be triggered by the exposureof the cellular substrate to one or more growth factors, examples ofwhich are insulin, epidermal growth factor (EGF) and platelet-derivedgrowth factor (PDGF). Such growth factor receptors are imbedded in andpenetrate through the cellular membrane. The inhibition of cellularreproduction is believed to occur when a growth factor binds to thecorresponding receptor on the external surface of the cellular membrane.This growth factor-receptor binding alters the chemical characteristicsof that portion of the receptor which exists within the cell and whichfunctions as an enzyme to catalyze phosphorylation of either anintracellular substrate or the receptor itself, the latter beingreferred to as autophosphorylation. Examples of such phosphorylationenzymes include tyrosine kinases, which catalyze phosphorylation oftyrosine amino acid residues of substrate proteins.

Many disease states that characterized by the uncontrolled reproductionof cells. These disease states involve a variety of cell types andinclude disorders such as leukemia, cancer, psoriasis, inflammatorydisease, bone diseases, atherosclerosis and restenosis occuringsubsequent to angioplastic procedures. This inhibition of tyrosinekinase is believed to have utility in the control of uncontrolledcellular reproduction, i.e., cellular proliferative disorders.

Initiation of autophosphorylation, i.e., phosphorylation of the growthfactor receptor itself, and of the phosphorylation of a host ofintracellular substrates are some of the biochemical events which areinvolved in mediator release mitogenesis and cell proliferation.Autophosphorylation of the insulin receptor and phosphorylation ofsubstrate proteins by other receptors are the earliest identifiablebiochemical hormonal responses.

Elimination of the protein tyrosine kinase (PTK) activity of the insulinreceptor and of the epidermal growth factor (EGF) receptor bysite-directed mutagenesis of the cellular genetic material which isresponsible for generation of insulin and EGF results in the completeelimination of the receptor's biological activity. This is notparticularly desirable because insulin is needed by the body to performother biological functions which are not related to cell proliferation.Accordingly, compounds which inhibit the PTK portion of the EGF and/orPDGF receptor at concentrations less than the concentrations needed toinhibit the PTK portion of the insulin receptor could provide valuableagents for selective treatment of cell proliferation disorders.

REPORTED DEVELOPMENTS

It has been reported that the most potent inhibitors of EGF receptorsInhibit EGF-induced proliferation of A431/clone 15 cells with little orno effect on the proliferation of such cells when induced by othergrowth factors. It has been reported also that erbstatin inhibits theautophosphorylation of the EGF receptor in membranes of A431 cells.Higher concentrations of erbstatin are required to inhibit cyclicadenosine 3',5'-monophosphate (cAMP)-dependent protein kinase.

SUMMARY OF THE INVENTION

In accordance with the present invention, there is provided a method ofinhibiting abnormal cell proliferation in a patient suffering from adisorder characterized by such proliferation comprising theadministration to a patient of an EGF and/or PDGF receptor inhibitingeffective amount of a bis mono- and/or bicyclic aryl compound exhibitingprotein tyrosine kinase inhibition activity wherein each aryl group is aring system containing 0-4 hetero atoms, said compound being optionallysubstituted or polysubstituted.

Another aspect of the present invention relates to pharmaceuticalcompositions comprising, in admixture with a pharmaceutically acceptablecarrier, a pharmaceutically effective amount of a compound of theaforementioned type. Another aspect of this invention comprisescompounds useful in the practice of the present method.

With respect to the method aspects of this invention, the compoundsdescribed by Formula I below constitute a class of the aforementionedbis mono- and/or bicyclic aryl, heteroaryl, carbocyclic orheterocarbocyclic compounds for use in the practice of the presentinvention: ##STR1## where:

Ar I and Ar II are independently a substituted or unsubstituted mono- orbicyclic ring, said rings optionally substituted with 0 to about 3 Rgroups; and

X is (CHR₁)₀₋₄ or (CHR₁)_(m) --Z--(CHR₁)_(n) where Z is O, NR', S, SO orSO₂, m and n are 0-3 and m+n=0-3 and R₁ and R' are independentlyhydrogen or alkyl; or a pharmaceutically acceptable salt thereof.

Preferably, AR I is a substituted or unsubstituted mono- or bicyclicaryl or heteroaryl ring system of about 5 to about 12 atoms and whereeach monocyclic ring may contain 0 to about 3 hetero atoms, and eachbicyclic ring may contain 0 to about 4 hetero atoms selected from N, Oand S provided said hetero atoms are not vicinal oxygen and/or sulfuratoms and where the substituents may be located at any appropriateposition of the ring system and are described by R.;

Ar II may be as described for Ar I or at least one ring is a substitutedor unsubstituted saturated carbocyclic of about 3 to about 7 atoms whereeach monocyclic ring may contain 0 to about 2 hetero atoms, and eachbicyclic ring may contain 0 to about 4 hetero atoms selected from N, Oand S provided said hetero atoms are not vicinal oxygen and/or sulfuratoms and where the substituents may be located at any appropriateposition of the ring system and are described by R.

Preferred Ar I and Ar II monocyclic aryl or heteroaryl rings includesubstituted or unsubstituted benzene, pyrrole, thiophene, furan,thiazole, imidazole, pyrazole, 1,2,4-triazole, pyridine, 2(1H)-pyridone,4(1H)-pyridone, pyrazine, pyrimidine, pyridazine, isothiazole,isoxazole, s-triazine, oxazole and tetrazole.

Preferred Ar II carbomonocyclic rings include substituted andunsubstituted cycloalkanes such as cyclopentane, cyclohexane,cycloheptane and partially unsubstituted cycloalkanes such ascyclopent-1-ene and heteromonocyclic rings such as piperdine,piperazine, morpholine and pyrrolidine.

Preferred Ar I and Ar II bicyclic rings include substituted andunsubstituted bicyclic aryl and heteroaryl rings such as naphthalene,naphthyridine, benzofuran, benzothiophene, indole, 1H-indazole,indoline, benzopyrazole, 1,3-benzodioxole, benzoxazole, purine,coumarin, chromone, quinoline, isoquinoline, benzimidazole, quinazoline,pyrido 2,3-b!pyrazine, pyrido 3,4-b!pyrazine, pyrido 3,2-c!pyridazine,pyrido 3,4-b!-pyridine, pteridine, 2(1H)-quinolone, 1 (2H)-isoquinolone,1,4-benzisoxazine, benzothiazole, quinoxaline, quinoline-N-oxide,isoquinoline-N-oxide, quinoxaline-N-oxide, quinazoline-N-oxide,benzoxazine, phthalazine, or cinnoline.

Preferred Ar II carbobicyclic rings include substituted andunsubstituted bicycloalkanes such as tetralin, decaline and adamantaneand preferred heterobicyclic rings such as imidazolidine, chroman,indoline and quinuclidine

Preferred R substituents other than hydrogen include alkyl, alkenyl,phenyl, aralkyl, aralkenyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl,aralkoxy, acyloxy, halo, haloalkyl, nitro, amino, mono-anddi-alkylamino, acylamino, carboxy, carboxyalkyl, carbalkoxy,carbaralkoxy, carbalkoxyalkyl, carbalkoxyalkenyl, aminoalkoxy, amido,mono- and di-alkylamido and N,N-cycloalkylamido, phenyl, or benzoyl; andR and R together may also form a ketone group.

Preferred X moieties are (CHR₁)₀₋₂, CH₂ --Z--CH₂ or Z--CH₂, where Z isO, NR' or S;

A special embodiment of this invention includes those compounds whereone of Ar I or Ar II is an azidophenyl moiety.

A further special embodiment of this invention includes those compoundswhere Ar II is cycloalkyl. Preferred group include cyclopentyl,cyclohexyl and cycloheptyl.

As employed above and throughout this disclosure, the following terms,unless otherwise indicated, shall be understood to have the followingmeanings:

"Monocyclic aryl" means a carbocyclic and/or heterocyclic aromatic ring.Preferred rings include phenyl, thienyl, pyridyl, 2(1H)-pyridonyl,4(1H)-pyridonyl, furyl, pyrimidinyl, imidazolyl, thiazolyl, oxazolyl andtetrazolyl.

"Bicyclic aryl" means a bicyclic ring system composed of two fusedcarbocyclic and/or heterocyclic aromatic rings. Preferred rings includenaphthyl, indolyl, benzothienyl, benzofuranyl, quinolinyl, chromonyl, 1(2H)-isoquinolonyl, isoquinolinyl, benzimidazolyl, benzothiazolyl,quinoxalinyl, naphthyridinyl, cinnolinyl, phthalazinyl, pyrido2,3-b!pyrazine, pyrido 3,4b!pyrazine, pyrido 3,2-c!pyridazine, pyrido3,4-b!-pyridine, pteridine, and quinazolinyl.

"Alkyl" means a saturated aliphatic hydrocarbon, either branched- orstraight-chained. Preferred alkyl is "loweralkyl" having about 1 toabout 6 carbon atoms. Examples of alkyl include methyl, ethyl, n-propyl,isopropyl, butyl, sec-butyl, t-butyl, amyl and hexyl.

"Alkoxy" refers to an alkyl-O-group. Preferred alkoxy groups includemethoxy, ethoxy, propoxy and butoxy.

"Aryloxy" refers to an aryl-O-group. The preferred aryloxy group isphenoxy.

"Aralkyl" means an alkyl group substituted by an aryl radical. Thepreferred aralkyl groups are benzyl or phenethyl.

The preferred aralkoxy groups are benzyloxy and phenethoxy.

The preferred acyloxy groups are acetoxy and benzyloxy;

"Halo" means halogen. Preferred halogens include chloride, bromide andfluoride.

The preferred haloalkyl group is trifluoromethyl.

The more preferred compounds of this invention include those compoundsof Formula I where Ar I and Ar II are independently phenyl, naphthyl,2(1H)-pyridonyl, pyridyl, quinolinyl, thienyl, 1 (2H)-isoquinolonyl,indolyl, napthyridenyl, pyrido 2,3-b!pyrazine, pyrido 3,4-b!pyrazine,pyrido 3,2-c!pyridazine, pyrido 3,4-b!-pyridine, pteridine,benzothiazolyl, quinoxalinyl, benzimidazolyl, quinolinyl-N-oxide,isoquinolinyl-N-oxide, quinazolinyl, quinoxalinyl-N-oxide,quinazolinyl-N-oxide, benzoxazinyl, phthalazinyl, or cinnolinyl; and Ris hydrogen, alkyl, alkoxy, hydroxy, halo or trifluoromethyl.

More specifically the compounds described by this invention are shown bythe following representative subgeneric formulae Ia-Iw: ##STR2##

It should be understood that the R groups which are substituted in theabove formulae Ia-Iw are located at any suitable and compatible positionof each of the rings of the bicyclic system.

A special embodiment of this invention includes those compounds of theabove formulae Ia-Iw where Ar II is thienyl, phenyl, naphthyl, pyridyl,quinolinyl, indolyl, furanyl, imidazolyl, 2(1H)-pyridonyl, 1(2H)-isoquinolonyl, thiazolyl and cycloalkyl, Phenyl, thienylnaphthyl,or cycloalkyl are preferred.

A further special embodiment of this invention includes those compoundswhich are most preferred. These are described by the following formulae:##STR3## wherein

Ar II is phenyl, naphthyl, thienyl, cyclohexyl or cyclopentyl; and

X is a bond, methyl, ethyl, propyl or (CHR₁)_(m) --Z--(CHR₁)_(n) where Zis O, NR', and n and m are 0-1 and n+m is 0 or 1.

The preferred classes of compounds include: ##STR4##

Compounds within the scope of this invention inhibit the growth factorinduced autophosphorylation of PDGF and/or EGF receptors. It is believedthat therapeutically useful PTK inhibiting compounds should not haveappreciable activity as inhibitors of serine or threonine kinasesystems. In addition these compounds should inhibit growthfactor-induced cell proliferation. Compounds meeting these criteria areof considerable value and are particularly useful in the practice of thepresent invention. Compounds exhibiting selectivity for either of theabove receptors are described herein.

The most preferred compounds are described where R is hydroxy, methoxy,ethoxy, chloro, bromo, fluoro or trifluoromethyl.

It is intended that the N-oxides of the above-described N-heteroarylrings are encompassed within the scope of this invention.

The compounds of this invention may be useful in the form of the freebase, in the form of salts and as a hydrate. All forms are within thescope of the invention. Acid addition salts may be formed and are simplya more convenient form for use; and in practice, use of the salt forminherently amounts to use of the base form. The acids which can be usedto prepare the acid addition salts include preferably those whichproduce, when combined with the free base, pharmaceutically acceptablesalts, that is, salts whose anions are non-toxic to the animal organismin pharmaceutical doses of the salts, so that the beneficial propertiesinherent in the free base are not vitiated by side effects ascribable tothe anions. Although pharmaceutically acceptable salts of said basiccompound are preferred, all acid addition salts are useful as sources ofthe free base form even if the particular salt per se is desired only asan intermediate product as, for example, when the salt is formed onlyfor purposes of purification and identification, or when it is used asan intermediate in preparing a pharmaceutically acceptable salt by ionexchange procedures.

Pharmaceutically acceptable salts within the scope of the inventioninclude those derived from the following acids: mineral acids such ashydrochloric acid, sulfuric acid, phosphoric acid and sulfamic acid; andorganic acids such as acetic acid, citric acid, lactic acid, tartaricacid, malonic acid, methanesulfonic acid, ethanesulfonic acid,benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid,quinic acid, and the like.

The corresponding acid addition salts comprise the following:hydrochloride, sulfate, phosphate, sulfamate, acetate, citrate, lactate,tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate,p-toluenesulfonate, cyclohexylsulfamate and quinate, respectively.

The acid addition salts of the compounds of this invention are preparedeither by dissolving the free base in aqueous or aqueous-alcoholsolution or other suitable solvents containing the appropriate acid andisolating the salt by evaporating the solution, or by reacting the freebase and acid in an organic solvent, in which case the salt separatesdirectly or can be obtained by concentration of the solution.

The compounds of this invention may be prepared by employing proceduresknown in the literature starting from known compounds or readilypreparable intermediates. Exemplary general procedures follow.

In general the compounds useful for the method of inhibiting cellproliferation may be prepared by the coupling reaction of a palladiumcatalyzed aryl or heteroaryistannane with an aryl or heteroarylhalide ortriflate. ##STR5## where X is halogen or triflate and Y istrialkylstannane and R and n are as previously described.

Preparation of aryl or heteroaryl substituted quinolines may be preparedas follows. ##STR6##

The triflate may be prepared from the corresponding alcohol with triflicanhydride (trifluoromethanesulfonic anhydride) in pyridine ##STR7##

Other triflates suitable for coupling with the aryl andheteroarylstannanes may be prepared in a similar manner. ##STR8##

Triflates may also be prepared from 2(1 H) or 4(1 H) quinolones as shownby the following. ##STR9##

The triflimide such as used in the above reaction may also be used toprepare compounds having a particular substitution such as the followingcompound. ##STR10##

The aryl and heteroarylstannanes may be prepared from the correspondinghalide (preferably bromide or iodide) by conversion to the aryllithium(by reaction with t-butyl-lithium at decreased temperatures, preferablyabout -78° C. followed by reaction with a halotrialkylstannane. Thefollowing reaction schemes give a representative list of stannanesprepared and the reaction conditions involved. ##STR11##

Further methods which may be employed in the preparation of stannanes ofthis invention include the following.

(1.) by the action of trimethyltin sodium on aryl halides as describedin Chem. Pharm. Bull. 1982, 30, 1731-1737: ##STR12## (2.) by heteroatomdirected aromatic lithiation process: ##STR13## (3.) by halogen-lithiumexchange: ##STR14##

The following are representative coupling reactions which show thepreparation of compounds used for the inhibition of cell proliferation##STR15##

Of course various methods may be employed depending on the reactantsinvolved. Thus, for example, in order to prepare ##STR16## the followingmethods may be used: ##STR17##

When it is desired that the final product include a 2-(1H) pyridone or4-(1H) pyridone ring then it is convenient to carry out the condensationon the 2- or 4-alkoxy pyridine followed by selective dealkylation. Thiscan be seen by the following representative scheme. ##STR18##

More specifically preparation of aryl or heteroaryl substituted2(1H)-pyridones may be found in U.S. Pat. Nos. 3,715,358; 3,718,743;4,465,686 and 4,599,423. Substituted phenyl pyridine preparation may befound in J. Am. Chem. Soc. 111, 877-891 (1989).

Thus it will be a matter of condensing two rings as shown above underthe methods described and/or in the art in order to obtain the compoundsuseful in the practice of inhibition of cell proliferation of thisinvention. The following representative compounds are prepared as shownbelow:

5-(2,4,5-trihydroxyphenyl)-2(1H)-pyridone,

5-(1,4-dihydroxynaphth-2-yl)-2(1H)-pyridone,

5-(2,5-dihydroxyphenyl)-2(1H)-pyridone,

5-(2,5-dihydroxy-4-t-butylphenyl)-2(1H)-pyridone,

3-(2,5-dihydroxyphenyl)-4(1H)-pyridone,

3-(2,5-dihydroxy-4-t-butylphenyl)-4(1H)-pyridone,

3-(thien-3-yl)-6,7-dimethoxyquinoline,

3-(pyrid-3-yl)indole,

2-(2,5-dihydroxy-4t-butylphenyl)pyridine and

4-(2,5-dihydroxyphenyl)-1(2H)-isoquinolone. ##STR19##

The compounds of the present invention may be prepared by the followingrepresentative examples.

EXAMPLE 1

2-methoxy-5-trimethylstannylpyridine

A solution of 1.74 g (9.26 mmol) of 2-methoxy-5-bromopyridine, 3.84 mL(6.07 g; 18.5 mmol) of hexamethylditin and 516 mg (0.446 mmol) of Pd(PPh3)4 in mL of dry toluene is flushed thoroughly with nitrogen andheated to 90° C. for 4 hours. The mixture is then evaporated andchromatographed on silica gel (eluting with hexane and then with 95:5hexane/ethyl acetate) to give 2-methoxy-5-trimethylstannylpyridine as acolorless oil which is used directly in the next step.

EXAMPLE 2

When the procedure of Example 1 is followed and2-methoxy-5-bromopyridine is replaced by the compounds of Table I below,then the compounds of Table II below are prepared. (Methods outlined onpages 14 and may also be used.)

TABLE I

2-methoxyphenyl bromide

3-methoxyphenyl bromide

4-methoxyphenyl bromide

2,3-dimethoxyphenyl bromide

2,4-dimethoxyphenyl bromide

2,5-dimethoxyphenyl bromide

2,6-dimethoxyphenyl bromide

3,4-dimethoxyphenyl bromide

3,5-dimethoxyphenyl bromide

3,4,5-trimethoxyphenyl bromide

2,3,4-trimethoxyphenyl bromide

2,5-dimethoxy-4-t-butylphenyl bromide

2,5-dimethoxy-4-phenylphenyl bromide

2,4dimethylphenyl bromide

2,5-dimethylphenyl bromide

2-methyl-5-methoxyphenyl bromide

4-chlorophenyl bromide

4-fluorophenyl bromide

2,5-dichlorophenyl bromide

3,4-dichlorophenyl bromide

4-dimethylaminophenyl bromide

4-acetylaminophenyl bromide

4-(N,N-dimethylaminocarbonyl)phenyl bromide

4-t-butoxycarbonylphenyl bromide

4-(pyrrolidinocarbonyl)phenyl bromide

3,5-bis(trifluoromethyl)phenyl bromide

4-bromobiphenyl

2-bromopyridine

3-bromopyridine

4-bromopyridine

2-methoxy-5-bromopyridine

4-methoxy-5-bromopyridine

6-methoxy-5-bromopyridine

2,3-dimethoxy-5-bromopyridine

2,4-dimethoxy-5-bromopyridine

2-acetylamino-5-bromopyridine

2-bromothiophene

3-bromothiophene

2-methoxy-3-bromothiophene

2-methoxy-4-bromothiophene

2-methoxy-5-bromothiophene

3-methoxy-5-bromothiophene

4-methoxy-2-bromothiophene

3-bromofuran

t-butyl 5-bromo-2-furoate

2-bromothiazole

2-bromooxazole

1-methyl-3-bromopyrazole

5-bromopyrimidine

2-bromopyrazine

4-bromopyridazine

'-bromonaphtbalene

2-bromonaphthalene

2-bromo-6-methoxynaphthalene

2-bromo-6,7-dimethoxynaphthalene

2-bromoquinoline

3-bromoquinoline

4-bromoquinoline

5-bromoquinoline

6-bromoquinoline

6,7-dimethoxy-3-bromoquinoline

6-methoxy-3-bromoquinoline

7-methoxy-3-bromoquinoline

7,8-dimethoxy-3-bromoquinoline

6,7-dichloro-3-bromoquinoline

4-bromoisoquinoline

3-bromoisoquinolihne

1-bromoisoquinoline

6,7-dimethoxy-3-bromoisoquinoline

N-methanesulfonyl-3-bromoindole

N-methanesulfonyl-5-brqmoindole

N-methanesulfonyl-3-bromo-5-methoxyindole

N-methanesulfonyl-3-bromo-5-chloroindole

2-bromobenzothiophene

3-bromobenzothiophene

8-bromopurine

7-methyl-2-bromopurine

3-bromopyrido- 3,4-b!-pyridine

TABLE II

2-methoxyphenyl trimethylstannane

3-methoxyphenyl trimethylstannane

4-methoxyphenyl trimethylstannane

2,3-dimethoxyphenyl trimethylstannane

2,4-dimethoxyphenyl trimethylstannane

2,5-dimethoxyphenyl trimethylstannane

2,6-dimethoxyphenyl trimethylstannane

3,4dimethoxyphenyl trimethylstannane

3,5-dimethoxyphenyl trimethylstannane

3,4,5-trimethoxyphenyl trimethylstannane

2,3,4-trimethoxyphenyl trimethylstannane

2,5-dimethoxy-4-t-butylphenyl trimethylstannane

2,5-dimethoxyphenylphenyl trimethylstannane

2,4-dimethylphenyl trimethylstannane

2,5-dimethylphenyl trimethylstannane

2-methyl-5-methoxyphenyl trimethylstannane

4-chlorophenyl trimethylstannane

4-fluorophenyl trimethylstannane

2,5-dichlorophenyl trimethylstannane

3,4-dichlorophenyl trimethylstannane

4-dimethylaminophenyl trimethylstannane

4-acetylaminophenyl trimethylstannane

4-(N,N-dimethylaminocarbonyl)phenyl trimethylstannane

4-t-butoxycarbonylphenyl trimethylstannane

4-(pyrrolidinocarbonyl)phenyl trimethylstannane

3,5-bis(trifluoromethyl)phenyl trimethylstannane

4-trimethylstannylbiphenyl

2-trimethylstannylpyridine

3-trimethylstannylpyridine

4-trimethylstannylpyridine

2-methoxy-5-trimethylstannylpyridine

4-methoxy-5-trimethylstannylpyridine

6-methoxy-5-trimethylstannylpyridine

2,3-dimethoxy-5-trimethylstannylpyridine

2,4-dimethoxy-5-trimethylstannylpyridine

2-acetylamino-5-trimethylstannylpyridine

2-trimethylstannylthiophene

3-trimethylstannylthiophene

2-methoxy-3-trimethylstannylthiophene

2-methoxy-4-trimethylstannylthiophene

2-methoxy-5-trimethylstannylthiophene

3-methoxy-5-trimethylstannylthiophene

4-methoxy-2-trimethylstannylthiophene

3-trimethylstannylfuran

t-butyl 5-trimethylstannyl-2-furoate

2-trimethylstannylthiazole

2-trimethylstannyloxazole

1-methyl-3-trimethylstannylpyrazole

5-trimethylstannylpyrmidine

2-trimethylstannylpyrazine

4-trimethylstannylpyridazine

1-trimethylstannylnaphthalene

2-trimethylstannylnaphthalene

2-trimethylstannyl-6-methoxynaphthalene

2-trimethylstannyl-6,7-dimethoxynaphthalene

2-trimethylstannylquinoline

3-trimethylstannylquinoline

4-trimethylstannylquinoline

5-trimethylstannylquinoline

6-trimethylstannylquinoline

6,7-dimethoxy-3-trimethylstannylquinoline

6-methoxy-3-trimethylstannylquinoline

7-methoxy-3-trimethylstannylquinoline

7,8-dimethoxy-3-trimethylstannylquinoline

6,7-dichloro-3-trimethylstannylquinoline

4-trimethylstannylisoquinoline

3-trimethylstannylisoquinoline

1-trimethylstannylisoquinoline

6,7-dimethoxy-3-trimethylstannylisoquinoline

N-methanesulfonyl-3-trimethylstannylindole

N-methanesulfonyl-5-trimethylstannylindole

N-methanesulfonyl-3-trimethylstannyl-5-methoxyindole

N-methanesulfonyl-3-trimethylstannyl-5-choroindole

2-trimethylstannylbenzothiophene

3-trimethylstannylbenzothiophene

8-trimethylstannylpurine

7-methyl-2-trimethylstannylpurine

3-trimethylstannylpyrido- 3,4-b!-pyridine

EXAMPLE 3

6,7-dimethoxyquinolin-3-yl trifluoromethanesulfonate,

A solution of 1.84 g (8.98 mmol) of 3-hydroxy-6,7-dimethoxyquinoline inmL of dry pyridine is cooled to 0° C. and 3.20 mL (5.38 g; 19.1 mmol) oftrifluoromethanesulfonic anhydride is added via syringe. The solution isallowed to warm to 22° C. and stirred for 4 hours. The solution is thenpartitioned between ethyl acetate (150 mL) and water (100 mL). Theaqueous layer is back extracted with ethyl acetate (100 mL) and thecombined organics dried (Na₂ SO₄) and evaporated. The resulting residueis chromatographed on silica gel (eluting with chloroform) to give awhite solid which is recrystallized from hexane to give6,7-dimethoxyquinolin- 3-yl trifluoromethane-sulfonate. mp 82.5°-85° C.)

EXAMPLE 4

When the procedure of Example 3 is followed and3-hydroxy-6,7-dimethoxyquinoline is replaced by the compounds of TableIII below, then the products of Table IV are prepared

TABLE III

phenol

2-methoxyphenol

3-methoxyphenol

4-methoxyphenol

2,3-dimethoxyphenol

3,4-dimethoxyphenol

3,5-dimethoxyphenol

3,4,5-trimethoxyphenol

2-chlorophenol

3-chlorophenol

4-chlorophenol

4-bromophenol

2,4-dichlorophenol

2,5-dichlorophenol

3,5-dichlorophenol

3,5-bis(trifluoromethyl)phenol

3-dimethylaminophenol

o-cresol

m-cresol

p-cresol

α,α,α-trifluoro-p-cresol

3-ethylphenol

4-tert-butylphenol

2,4-dimethylphenol

2,5-dimethylphenol

3,4-dimethylphenol

4-benzyloxyphenol

4-phenylphenol

2-phenylphenol

2,3,5-trimethyphenol

4-nitrophenol

4-acetylaminophenol

2-bromo-4-methylphenol

3'-hydroxyacetophenone

4'-hydroxyacetophenone

methyl 3-hydroxybenzoate

methyl 4-hydroxy-3-methoxybenzoate

N,N-dimethyl-4-hydroxybenzamide

1-naphthol

2-naphthol

6-methoxy-1-naphthol

6-methoxy-2-naphthol

6,7-dimethoxy-1-naphthol

6,7-dimethoxy-2-naphthol

5,8-dimethoxy-2-naphthol

6-bromo-2-naphthol

2-hydroxyquinoline

2-hydroxy-4-methylquinoline

6,7-dimethoxy-2-hydroxyquinoline

3-hydroxyquinoline

4-hydroxyquinoline

6,7-dimethoxy-4-hydroxyquinoline

7-chloro-4-hydroxyquinoline

1-hydroxyisoquinoline

5-hydroxyisoquinoline

2-hydroxypyridine

3-hydroxypyridine

4-hydroxypyridine

2,3-dimethoxy-5-hydroxypyridine

5-chloro-2-pyridinol

5-chloro-3-pyridinol

3-hydroxypicolinamide

TABLE IV

phenyl trifluoromethane sulfonate

2-methoxyphenyl trifluoromethane sulfonate

3-methoxyphenyl trifluoromethane sulfonate

4-methoxyphenyl trifluoromethane sulfonate

2,3-dimethoxyphenyl trifluoromethane sulfonate

3,4-dimethoxyphenyl trifluoromethane sulfonate

3,5-dimethoxyphenyl trifluoromethane sulfonate

3,4,5-trimethoxyphenyl trifluoromethane sulfonate

2-chlorophenyl trifluoromethane sulfonate

3-chlorophenyl trifluoromethane sulfonate

4-chlorophenyl trifluoromethane sulfonate

4-bromophenol trifluoromethane sulfonate

2,4-dichlorophenyl trifluoromethane sulfonate

2,5-dichlorophenyl trifluoromethane sulfonate

3,5-dichlorophenyl trifluoromethane sulfonate

3,5-bis(trifluoromethyl)phenyl trifluoromethane sulfonate

3-dimethylaminophenyl trifluoromethane sulfonate

o-cresyl trifluoromethane sulfonate

m-cresyl trifluoromethane sulfonate

p-cresyl trifluoromethane sulfonate

α,α,α-trifluoro-p-cresyl trifluoromethane sulfonate

3-ethylphenyl trifluoromethane sulfonate

4-tert-butylphenyl trifluoromethane sulfonate

2,4dimethylphenyl trifluoromethane sulfonate

2,5-dimethylphenyl trifluoromethane sulfonate

3,4-dimethylphenyl trifluoromethane sulfonate

4-benzyloxyphenyl trifluoromethane sulfonate

2-phenylphenyl trifluoromethane sulfonate

4-phenylphenyl trifluoromethane sulfonate

2,3,5-trimethyphenyl trifluoromethane sulfonate

4-nitrophenyl trifluoromethane sulfonate

4-acetamidophenyl trifluoromethane sulfonate

2-bromo-4-methylphenyl trifluoromethane sulfonate

3-acetylphenyl trifluoromethane sulfonate

4-acetylphenyl trifluoromethane sulfonate

3-methoxycarbonylphenyl trifluoromethane sulfonate

2-methoxy-4-methoxycarbonylphenyl trifluoromethane sulfonate

4-N,N-dimethylaminocarbonylphenyl trifluoromethane sulfonate

naphth-1-yl trifluoromethane sulfonate

naphth-2-yl trifluoromethane sulfonate

6-methoxynaphth-1-yl trifluoromethane sulfonate

6-methoxynaphth-2-yl trifluoromethane sulfonate

6,7-dimethoxynaphth-1-yl trifluoromethane sulfonate

6,7-dimethoxynaphth-2-yl trifluoromethane sulfonate

5,8-dimethoxynaphth-2-yl trifluoromethane sulfonate

6-bromonaphth-2-yl trifluoromethane sulfonate

quinolin-2-yl trifluoromethane sulfonate

4-methylquinolin-2-yl trifluoromethane sulfonate

6,7-dimethoxyquinolin-2-yl trifluoromethane sulfonate

quinolin-2-yl trifluoromethane sulfonate

quinolin-4-yl trifluoromethane sulfonate

6,7-dimethoxyquinolin-4-yl trifluoromethane sulfonate

7-chloroquinolin-4-yl trifluoromethane sulfonate

isoquinolin-1-yl trifluoromethane sulfonate

isoquinolin-5-yl trifluoromethane sulfonate

pyridin-2-yl trifluoromethane sulfonate

pyridin-3-yl trifluoromethane sulfonate

pyridin-4-yl trifluoromethane sulfonate

2,3-dimethoxypyridin-5-yl trifluoromethane sulfonate

5-chloro-2-pyridin-2-yl trifluoromethane sulfonate

5-chloro-3-pyridinyl trifluoromethane sulfonate

picolin-3-amido trifluoromethane sulfonate

EXAMPLE 5

2.5-dimethoxy-4-t-butylphenyl iodide

A stirred solution of 3.00 g (15.5 mmol) of1,4-dimethoxy-2-t-butylbenzene (obtained by methylation of t-butylhydroquinone with sodium hydride and methyl iodide in tetrahydrofuran)and 2.52 g (21.7 mmol) of tetramethylethylenediamine in 50 mL ofanhydrous ether under nitrogen is cooled to 0° C. and 8.66 mL (21.7mmol) of n-butyllithium (2.5M in hexane) is added over a 5 minuteperiod. The mixture is warmed to 22° C., stirred for 18 hours and thencooled back to 0° C. The reaction is quenched with 7.86 g (30.9 mmol) ofiodine in 30 mL of tetrahydrofuran and partitioned between ethyl acetate(200 mL) and 10% NaHSO3 (300 mL). The organic layer is washed with water(50 mL), brine (50 mL), dried (MgSO4) and evaporated to give a brown,partially crystalline oil which is chromatographed on silica gel(eluting with 98:2 hexane/ethyl acetate) to give crude product which isrecrystallized from hexane to obtain 2,5-dimethoxy-4-t-butylphenyliodide m p 8.5°-82.5° C.)

EXAMPLE 6

When the procedure of Example 5 is followed and the appropriate startingmaterial is used, the following compounds of Table V may be prepared.

TABLE V

2,3-dimethoxyphenyl iodide

2,3,4-trimethoxyphenyl iodide

2,4-dimethoxy-3-t-butylphenyl iodide

4-iodo-1,3-benzodioxole

EXAMPLE 7

5-(3,4-dimethoxyphenyl)-2-methoxypyridine

A solution of 2.00 g (6.64 mmol) of 4-trimethylstannylveratrole, 2.49 g(13.2 mmol) of 2-methoxy-5-bromopyridine and 370 mg (0.332 mmol) of Pd(PPh₃)₄ in 30 mL of dry dimethylformamide is flushed thoroughly withnitrogen and heated to 90° C. for 12 hours. The reaction mixture ispartitioned between ethyl acetate (150 mL) and water (100 mL). Theaqueous layer is back extracted with ethyl acetate (100 mL) and thecombined organics are washed with brine (75 mL), dried (MgSO₄) andevaporated to give a crude yellow oil. The oil is chromatographed onsilica gel (eluting with 95:5 hexane/ethyl acetate and then with 9:1hexane/ethyl acetate) which gives5-(3,4-dimethoxy-phenyl)-2-methoxypyridine m.p 83°-84° C.)

EXAMPLE 8

When the procedure of Example 7 is followed and2-methoxy-5-bromopyridine is replaced with the bromo compounds ofExample 2, Table I, then the corresponding products are obtained.

EXAMPLE 9

When the procedure of Example 7 is followed and4-trimethylstannylveratrole is replaced by the stannanes of Example 2,Table II, then the corresponding products are obtained.

EXAMPLE 10

When the procedure of Example 7 is followed and2-methoxy-5-bromopyridine is replaced with the bromo compounds ofExample 2, Table I and 4-trimethylstannylveratrole is replaced by thestannanes of Example 2, Table II, then the corresponding products areobtained. A representative list of compounds so prepared are shown belowIn Table VI.

TABLE VI

2-(2,3,4-trimethoxyphenyl)pyridine

2,3-dimethoxy-6-(thien-3-yl)naphthaylene

3-(2,3-dimethoxypbenyl)quinoline

3-(benzothien-3-yl)quinoline

4-(phenyl)phenyl-1,4-dimethoxybenzene

2-(2,5-dimethoxyphenyl)naphthaylene

5-(2,5-dimethoxyphenyl)pyrimidine

5-phenyl-1,2,4-trimethoxybenzene

2-methoxy-5-(2,3,5-trimethoxyphenyl)pyridine

2-methoxy-5-(1,4-dimethoxynaphth-2-yl)pyridine

3-(2,5-dimethoxyphenyl)thiophene

2-methoxy-5-(2,5-dimethoxy-4-phenyl)phenylpyridine

3,6-dihydroxy-4-phenylveratrole

4-(2,5-dimethoxyphenyl)veratrole

EXAMPLE 11

3-(2-methoxypyridin-5,yl)-6,7-dimethoxyquinoline

A mixture of 800 mg (2.94 mmol) of2-methoxy-5-trimethylstannyl-pyridine, mg (2.94 mmol) of6,7-dimethoxyquinolin-3-yl trifluoromethane sulfonate, 374 mg (8.82mmol) of anhydrous lithium chloride and 170 mg (0.147 mmol) ofPd(PPh₃)hd in 15 mL of anhydrous dioxane is flushed thoroughly withnitrogen and refluxed for 6 hours. The mixture is diluted with ethylacetate (100 mL), washed with saturated NaHCO₃ (75 mL), dried (Na₂ SO₄)and evaporated. The resulting residue is chromatographed on silica gel(eluting with chloroform) to give a solid material which isrecrystallized from ethyl acetate to give3-(2-methoxypyrid-5-yl)-6,7-dimethoxyquinoline m.p. 170.5°-171.5° C.

EXAMPLE 12

When the procedure of Example 11 is followed and2-methoxy-5-trimethylstannylpyridine is replaced by the stannanes ofExample 2, Table II, then the corresponding products are obtained.

EXAMPLE 13

When the procedure of Example 11 is followed and6,7-dimethoxy-quinolin-3-yl trifluoromethane sulfonate is replaced bythe triflates of Example 4, Table IV, then the corresponding productsare prepared.

EXAMPLE 14

When the procedure of Example 11 is followed and2-methoxy-5-trimethylstannylpyridine is replaced by the stannanes ofExample 2, Table II, and 6,7-dimethoxyquinolin-3-yl trifluoromethanesulfonate is replaced by the triflates of Example 4, Table IV, then thecorresponding products are prepared. A representative list of compoundsso prepared is shown below in Table VII.

TABLE VII

3-(thien-3-yl)-6,7-dimethoxyquinoline, mp. 116°-118° C.

2-methoxy-5-(3,4,5-trimethoxyphenyl)pyridine, m.p. 71°-72° C.

4-(thien-3-yl)-6,7-dimethoxyquinoline, m.p. 134°-135° C.

2-(thien-3-yl)-6,7-dimethoxyquinoline, 135.5°-138° C.

3-(quinolin-3-yl)-6,7-dimethoxyquinoline, m.p. 190.5°-191° C.

3-(thien-3-yl)-6,7-dichloroquinoline, m.p. 167°-167.5° C.

3-(thien-3-yl)-7-methoxyquinoline, m.p. 122°-124° C.

3-(3,4-dichlorophenyl)-6,7-dimethoxyquinoline, m.p. 184°-186° C.

3-(4-methoxyphenyl)-6,7-dimethoxyquinoline, m.p. 162.5°-164.5° C.

3-(naphth-2-yl)-6,7-dimethoxyquinoline, m.p. 162.50°-165° C.

3-(4-phenyl)phenyl-6,7-dimethoxyquinoline, m.p. 143°-145° C.

3-(thien-2-yl)-6,7-dimethoxyquinoline, m.p. 122.5°-124° C.

3-(5-methoxythien-2-yl)-6,7-dimethoxyquinoline (111°-113° C.

4-phenyl-6,7-dimethoxyquinoline, m.p. 124°-125° C.

3-(5-chlorothien-2-yl)-6,7-dimethoxyquinoline (131.5°-132° C.

3-(furan-3-yl)quinoline, m.p. 87°-90° C.

5-(2,5-dimethoxyphenyl)pyridine, m.p. 92.5°-94.5° C.

5-(2,5-dimethoxyphenyl)-2-methoxypyridine (oil)

EXAMPLE 15

2.methoxy-5- (2,5-dimethoxy-4-t-butyl)phenyl!pyridine

When the procedure of Example 7 is followed and4-trimethylstannylveratrole is replaced with2-methoxy-5-trimethylstannylpyridine and 2-methoxy-5-bromopyridine isreplaced with 2,5-dimethoxy-4-t-butylphenyl iodide from Example 5, thenthe compound prepared is 2-methoxy-5- (2,5-dimethoxy-4-t-butyl)phenyl!pyridine as an oil.

EXAMPLE 16

5 (2,5-dimethoxy-4-t-butyl)phenyl!pyridine

When 2-methoxy-5-trimethylstannylpyridine in Example 15 is replaced by5-trimethylstannylpyridine, the compound prepared is 5-(2,5-dimethoxy-4-t-butyl)phenyl! pyridine m.p. 92.5°-94.5° C.

EXAMPLE 17

5- (2,5-dihydroxy-4t-butyl)phenyl!-2(1H)-pyridone

A mixture of 252 mg (0.837 mmol) of 2-methoxy-5-(2,5-dimethoxy-4-t-butyl)-phenyl! pyridine and 7.0 g of pyridinehydrochloride is heated to 210° C. for 1 hour, cooled and diluted with60 mL of water. The mixture is cooled lo 0° C., filtered, andrecrystallized from methanol to obtain 5-(2,5-dihydroxy4-t-butyl)-phenyl!-2(1H)-pyridone m.p. 270°-5°C.(softens)>300° C.(dec)!.

EXAMPLE 18

5- (2,5-dihydroxy-4-t-butyl)phenyl)pyridine

When the procedure of Example 17 is followed and 2-methoxy-5-(2,5-dimethoxy-4-t-butyl)phenyl!pyridine is replaced by 5-2,5-dimethoxy-4-t-butyl)phenyl! pyridine, the product obtained is 5-(2,5-dihydroxy-4-t-butyl)phenyl! pyridine m.p. 202°-204° C.

EXAMPLE 19

5-(2,5-dihydroxyphenyl)-2(1H)-pyridone

A solution of 502 mg (2.05 mmol) of2-methoxy-5-(2,5-dimethoxyphenyl)pyridine in 20 mL of 48% hydrobromicacid (aqueous) is refluxed for 6 hours, cooled to ca. 25° C. and dilutedwith 150 mL of water. The mixture is neutralized with solid NaHCO₃,cooled to 0° C. and the resulting solid product collected by filtration.The solid is washed well with water, collected by centrifugation, thenfurther purified by recrystalization in methanol to obtain5-(2,5-dihydroxyphenyl)-2(1H)-pyridone m.p. 303°-306° C. dec).

EXAMPLE 20

When the procedure of Example 19 is followed and2-methoxy-5-(2,5dimethoxyphenyl)pyridine is replaced by2-methoxy-5-(3,4-dimethoxyphenyl)pyridine,2-methoxy-5-(3,4,5-trimethoxyphenyl)pyridine or5-(2,5-dimethoxyphenyl)pyridine, then the compounds prepared are5-(3,4-dihydroxy-phenyl)-2(1H)-pyridone m.p. 307°-310° C.);5-(3,4,5-trihydroxyphenyl)-2(1H)-pyridone m.p. 300° C.) and5-(2,5-dihydroxyphenyl)pyridine m.p. 216°-218° C.).

EXAMPLE 21

When the procedure of Example 17 is followed and 2-methoxy-5-(2,5-dimethoxy-4-t-butyl)phenyl!pyridine is replaced by2-methoxy-5-(6,7-dimethoxy-quinolin-3-yl)pyridine and the reaction iscarried out at 160° C. for 5 minutes, then the product prepared is5-(6,7-dimethoxyquinolin-3-yl)-2(1H)-pyridone m.p. 259°-261° C.).

EXAMPLE 22

3-(6.7-dimethoxyquinolin-3-yl)pyridine

A solution of 600 mg (3.37 mmol) of methylN-2-(pyrid-3-yl)vinylcarbamate in 10 mL of 6N H₂ SO₄ is refluxed for 10minutes, cooled to 0° C. and basified to pH 11 with 50% NaOH. A solutionof 400 mg (2.03 mmol) of 2-amino-4,5-dimethoxybenzaldehyde isimmediately added and the mixture refluxed for 2.5 hours, cooled to 22°C. and partitioned between ether (150 mL) and water (100 mL). Theaqueous layer is back extracted with chloroform and the combinedorganics are dried (MgSO₄) and evaporated to obtain an oil which isrecrystallized from hexane/ethyl acetate twice to give3-(6,7-dimethoxyquinolin-3-yl)pyridine m.p. 131°-132° C.).

EXAMPLE 23

3-(indol-3-yl)-6.7-dimethoxyquinoline

A solution of 800 mg (5.03 mmol) of indol-3-ylacetaldehyde (obtainedfrom diisobutylaluminum hydride reduction of the ester and usedimmediately) and 800 mg (4.42 mmol) of 2-amino-4,5-dimethoxybenzaldehydein 15 mL of ethanol is flushed thoroughly with nitrogen, treated with0.5 mL of 1M NaOH and heated to 80° C. for 3 hours. The mixture iscooled to 22° C. and partitioned between chloroform (150 ml) and brine(100 mL). The organic layer is dried (MgSO₄) and evaporated and the darkbrown residue that results is chromatographed on silica gel (elutingwith 97.5:2.5 chloroform/methanol). The product obtained is furtherchromatographed on silica gel (eluting with 98:2 ethyl acetate/methanol)and the resulting product is recrystallized from ethyl acetate to give3-(indol-3-yl)-6,7-dimethoxyquinoline m.p. 204°-206° C.).

EXAMPLE 24

When the procedure of Example 23 is followed and2-amino-4,5-dimethoxybenzaldehyde is replaced with 2-aminobenzaldehyde,then the product prepared is 3-(indol-3-yl)quinoline m.p. 173°-175° C.).

EXAMPLE 25

When the procedure of Example 23 is followed and indol-3-yl-acetaldehydeis replaced by phenylacetaldehyde then the product prepared is3-phenyl-6,7-dimethoxyquinoline m.p. 126.5°-128° C.)

EXAMPLE 26

6,7-dimethoxy-4-hydroxy-3-(thien-3-yl)-2(1H)-quinoline

A mixture of (0.632g) 3,4-dimethoxyaniline, (1.00 g) diethylthien-3-ylmalonate and (20 ml) diphenyl ether are heated atapproximately 200° C. for 4 hours. The reaction mixture is extractedwith 0. IN NaOH solution and the alkaline solution then acidified withIN HCl and cooled in an ice water bath. The precipitate is collected,washed with ether and dried. The solid is then heated in EtOH, filteredand the filtrate evaporated in vacuo to give a light brown solid whichis triturated with ether, filtered, and dried to give6,7-dimethoxy-4-hydroxy-3-(thien-3-yl)-2(1H)quinoline m.p. 300° C.dec.).

EXAMPLE 27

2-(thien-2-yl)-4-carboxy-6,7-dimethoxyquinoline

To a boiling solution of 2-thiophenecarboxaldehyde (1.22 ml), pyruvicacid (0.904 ml) and 50 ml absolute EtOH is added dropwise a solution of3,4-dimethoxyaniline (2.00 g) in 100 ml EtOH. The mixture is refluxedfor approximately 4 hours, then stored at room temperature overnight.The greenish-yellow precipitate is collected by filtration, washed withfresh EtOH then with ether and allowed to air dry to obtain2-(thien-2-yl) carboxy-6,7-dimethoxyquinoline m.p. 260°-263° C.).

EXAMPLE 28

When the procedure of Example 26 is followed and2-thiophenecarboxaldehyde is replaced with 3-pyridinecarboxaldehyde or2-midazolcarboxaldehyde, then the products prepared are2-(pyrid-3-yl)-4-carboxy-6,7-dimethoxyquinoline m.p. 275° C. dec) and2-(imidazol-2-yl)-4-carboxy-6,7-dimethoxyquinoline m.p. 300° C. dec).

EXAMPLE 29

2-(N-phenylsulfonylindol-3-yl)-4-carboxy-6,7-dimethoxyquinoline

Pyruvic acid (0.486 ml) is added to a suspension of (2.00 g) ofN-phenyl-sulfonyl-3-indolecarboxaldehyde in 100 ml absolute EtOH. Themixture is heated to reflux and a solution of 3,4dimethoxyaniline (1.074g) in 50 ml absolute EtOH is added dropwise. The reaction is thenrefluxed for approximately three hours and stirred at RT for 72 hours.The yellow precipitate is collected by filtration, washed with EtOH thenwith ether and the solid collected. This is triturated with EtOAC/EtOHand dried and used directly in the next step.

EXAMPLE 30

2-(indol-3-yl)-4-carboxy-6,7-dimethoxyquinoline

A stirred solution of (0.547 g) of2-(N-phenylsulfonylindol-3-yl)-4-carboxy-6,7-dimethoxyquinoline, K₂ CO₃(0.380 g), MeOH (40 ml) and H₂ O (10 ml) are heated to reflux. The MeOHis evaporated in vacuo, and the aqueous residue diluted with more H₂ O,and acidified with 0.IN HCl to pH between 6°-7 while contained in anice-bath. An orange solid precipitates. This is collected, washed withether then dried under vacuum (0.1 mm at 22° C.) for a few hours toobtain 2-(indol-3-yl)-4-carboxy-6,7-dimethoxyquinoline m.p. 286° C.dec).

EXAMPLE 31

3-cyclohexylethyl-6,7-dimethoxyquinoline

Step A 3-cyclohexylethynyl-6,7-dimethoxyquinoline

This reaction is carried out under anhydrous conditions.Cyclohexylacetylene (700 mg; 6.47 mmol) in 10 mL. THF is cooled to 0° C.To this is added 2.5M n-BuLi (3.0 mL; 7.44 mmol) and stirred for 30 min.at 0° C. under N₂ atm and then 1.0M ZnCl₂ (7.4 mL; 7.44 mmol). This isallowed to warm to room temperature and stirred for 3/4 hour. Thereaction mixture is transferred via cannula to a flask containing6,7-dimethoxyquinolin-3-yl trifluoromethane sulfonate (500 mg; 1.48mmol) and Pd(PPh₃)4 (83 mg; 0.074 mmol) in 4 mL of THF. This is thenheated to 50° C. under N₂ for 41/2 hours. The reaction mixture is thenpoured into 90 mL of 10% NH₄ OH, diluted with CHCl₃ and stirred for 20min. The aqueous layer is separated, and the organic layer washed withbrine, dried over MgSO₄, filtered, evaporated and chromatographed with4:1 hexane: EtOAc to obtain 3-cyclohexylethynyl-6,7-dimethoxyquinoline,which is recrystallized from hexane, identified by NMR and used directlyin the next step.

Step B 3-cyclohexylethyl-6,7-dimethoxyquinoline

To 3-cyclohexylethynyl-6,7-dimethoxyquinoline (215 mg; 0.73 mmol) in10mL CH₃ OH and 20 mL glacial acetic acid is added 22 mg 10% Pd/C. H₂ isbubbled through the reaction mixture and then filtered, evaporated todryness and diluted with distilled water. This is then neutralized withNa₂ CO₃, extracted with EtOAc, washed with brine, dried (MgSO₄),evaporated to dryness and chromatographed with 8:2/hexane: EtOAc toobtain 3-cyclohexyl-ethyl-6,7-dimethoxyquinoline.

Calc'd: C: 76.22; H: 8.47; N: 4.69

Found: C: 75.08; H: 8.32; N: 4.59

EXAMPLE 32

3-benzyloxy-6,7-dimethoxyquinoline

To 3-hydroxy-6,7-dimethoxyquinoline (150 mg; 0.73 mmol) in 3 mL THF isadded benzyl bromide (0.13 mL; 188 mg; 1.10 mmol) and Nail (59 mg; 1.46mmol). This is stirred at room temperature for 1 hour and 25 mg of NaHadded followed by 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)pyrimidinone(DMPU)(255 mg; 2.07 mmol) and stirred at room temperature for 31/2hours. The reaction mixture is partitioned between EtOAc and distilledH₂ O and extracted 2× with EtOAc. The latter is washed with brine, dried(MgSO₄), filtered, evaporated to dryness and chromatographed with 1%MeOH/CHCl₃ to obtain 3-benzyloxy-6,7-dimethoxyquinoline m.p.146.5°-148.5° C.).

EXAMPLE 33

2,(thien-3-yl)-6,7-dimethylquinoxaline

Step A 3-thienylglyoxaldehyde hydrate

A mixture of selenium dioxide (5.276 g; 0.048 mol) in dioxane: water;95:5 is heated to solution. To this is added 3-acetylthiophene (4.00 g;0.032 mol) and the mixture refluxed for 5 hours. The precipitatedselenium is filtered off and the filtrate concentrated in vacuo to givea yellow oil which is purified by FPLC using 20%: 30%; EtoAc: hexane toobtain a yellow solid which is then recrystalized from water to obtain3-thienylglyoxaldehyde hydrate, which is used directly in the next step.

Step B 2-(thien-3-yl)-6,7-dimethylquinoxaline

To a cooled stirring solution of 4,5-diamino-o-xylene (1.00g; 6.3 mmol)in 20 ml. absolute ethanol is slowly added a solution of3-thienylglyoxaldehyde hydrate (0.662 g; 4.9 mmol) in 20 ml. absoluteethanol. The mixture is refluxed for 1.5 hours, cooled in an ice bath,filtered and the collected material is washed with hexane and dried invacuo to obtain 2-(thien-3-yl)-6,7-dimethylquinoxaline m.p. 142°-143.5°C.).

EXAMPLE 34

When the procedure of example 33 is followed, and 3-thienylglyoxaldehydeof Step B is replaced by the compounds of Table VIII, below and4,5-diamino-σ-xylene of Step B is replaced by the compounds of Table IX,below, then the corresponding products are obtained.

Table VIII

3-thienylglyoxaldehyde

glyoxal

phenylglyoxal

4-methoxy-α-oxobenzeneacetaldehyde

3-fluoro-4-methoxy-α-oxobenzeneacetaldehyde

α-oxo-γ-phenylbutyraldehyde

α-oxo-4-pyridineacetaldehyde

α-oxo-3-pyridineacetaldehyde

α-oxo-2-pyridineacetaldehyde

3,4-dimethoxy-α-oxobenzeneacetaldehyde

α-oxo-2-thiopheneacetaldehyde

α-oxo-3-thiopheneacetaldehyde

5-chloro-α-oxo-2-thiopheneacetaldehyde

5-fluoro-α-oxo-2-thiopheneacetaldehyde

2,3-butanedione

pyravic aldehyde

5-(4-chlorophenyl)-α-oxo-2-thiopheneacetaldehyde

5-(5-chloro-2-thienyl)-α-oxo-2-thiopheneacetaldehyde

4-cyano-α-oxobenzeneacetaldehyde

4-(1H-tetrazol-5-yl)-α-oxobenzeneacetaldehyde

5-bromo-α-oxo-2-thiophenacetaldehyde

TABLE IX

4,5-diamino-σ-xylene

1,2-diaminobenzene

4,5-dimethyl-1,2-diaminobenzene

4,5-dimethoxy-1,2-diaminobenzene

3,5-dimethyl-1,2-diaminobenzene

3,5-dimethoxy-1,2-diaminobenzene

2,3-diaminopyridine

3,4-diaminopyridine

3,4-diaminotoluene

4,5-diaminopyrimidine

4,5-diethyl-1,2-diaminobenzene

4,5-diethoxy-1,2-diaminobenzene

3,4-diaminobenzotrifluoride

4-tert-butyl-1,2-diaminobenzene

4-(4-pyridyl)-1,2-diaminobenzene

4-(3-pyridyl)-1,2-diaminobenzene

5-bromo-2,3-diaminopyridine

5-bromo-3,4-diaminopyridine

4-fluoro-1,2-diaminobenzene

2-bromo-4,5 -diamopyridine

3,4-diaminothiophene

1,2-diaminocyclohexane

EXAMPLE 35

3-phenoxy-6,7-dimethylquinoline

To a solution of Nail (1.2g; 60% disp in oil) in DMF (3 ml) is added3-hydroxy-6.7-dimethoxyquinoline (150 mg; 0.73 tool) and the reactionmixture is allowed to stir for 30 minutes at room temperature. To thisis added the tetrafluoroborate salt of chlorobenzene manganesetricarbonyl complex (prepared by J.O.C. 24: 1991;7092) (183 mg) andstirred for 3 hours. To this is added 20 ml of acetonitrile and stirredovernight. The reaction mixture is dissolved in EtOAc: brine andextracted 2× with EtOAc, washed with water 2×, washed with brine, dried(MgSO₄) and concentrated in vacuo to obtain a material which is purifiedby FPLC using 1% methanol: chloroform to obtain a solid which NMRindicates to be 3-phenoxy-6.7-dimethoxyquinoline. The hydrochloride saltis then prepared in the usual manner m.p. 224-226).

EXAMPLE 36

(6,7-dimethoxyquinazolin-4-yl)-alpha-naphthalenylamine

To a 25 mL flask with 10 ml of abs. EtOH is added 0.137 g of4-chloro-6,7-dimethoxyquinazoline and 0.087 g of 1-aminonaphthalene. Thesolution is heated to reflux whereupon the insoluble materials dissolve.After 5 minutes at reflux a precipatate forms. The solution is allowedto stir an additional 10 min before cooling and isolation of the productas the hydrochloride salt by simple filtration. High-vacuum drying ofthe solid provided analytically pure(6,7-dimethoxy-quinazolin-4-yl)-alpha-naphthalenylamine (0.142 g, whitepowder, m.p. 271°-273° C.

EXAMPLE 37

4-(m-chlorophenoxy)-6.7-dimethoxyquinazoline

THF (5 ml) and Nail (60% disp in oil, approx. 28 mg) is added to a dryflask maintained under inert atmosphere at room temperature.m-Chlorophenol (0.09 g) is added as a soln. in THP (1 mL) and stirringis continued until the solution became clear.4-Chloro-6,7-dimethoxyquinazoline is added all at once (as the solid)and stirring was maintained overnight at RT. The solution is partitionedbetween CH₂ CL₂ and 5% NaOH. The organic layer is washed with, brine,dried (Na₂ SO₄) and concentrated. Flash column chromatography (40%EtOAc/Hex) provided the pure compound. An analytical sample is obtainedby recrystallization from EtOAc/Hex to provide4-m-chlorophenoxy)-6,7-dimethoxyquinazoline (0.05 g, white needles, m.p.152°-153° C.

EXAMPLE 38

The above examples may be followed to prepare any of the desiredcompounds of this invention. A representative list of compounds whichmay be prepared are shown below in Table X.

TABLE X

3-(thien-3-yl)-6,7-dimethylquinoline, m.p. 132°-138° C.

3-(1-cyclopent-1-enyl)-6,7-dimethoxyquinoline hydrochloride, m.p.213°-215° C.

3-cyclopentyl-6,7-dimethoxyquinoline hydrochloride, m.p. 213.5°-215° C.

4-(3-phenylpropyloxy)-6,7-dimethoxyquinoline, m.p. 90°-91.5° C.

3-(thien-3-yl)-6,7-dimethoxy-2(1H)-quinolone, m.p. 264°-266° C.

3-(thien-3-yl)-6,7-dimethoxyquinoline-N-oxide, m.p. 207°-208° C.

3-(2-chlorothien-5-yl)-5,7-dimethoxyquinoline, m.p. 153°-154° C.

3-(3-fluoro-4-methoxyphenyl)-6,7-dimethoxyquinoline, m.p. 165.5°-167° C.

3-phenyl-4-carboxy-6,7-dimethoxyquinoline, m.p. 259°-262° C.

3-(3-fluorophenyl)-6,7-dimethoxyquinoline, m.p. 156°-158° C.

4-(2-phenylethoxy)-6,7-dimethoxyquinoline, m.p. 117.5°-118.5° C.

3-(4-methoxybenzyloxy)-6,7-dimethoxyquinoline, m.p. 115.5°-118° C.

3-(3-fluoro-4-methoxyphenyl)-7-fluoroquinoline, m.p. 138°-140.5° C.

2-chloro-3-(thien-3-yl)-6,7-dimethoxyquinoline, m.p. 138.5°-139.5° C.

2-methyl-3-(thien-3-yl)-6,7-dimethoxyquinoline, m.p. 132°-132.5° C.

3-(thien-3-yl)-5-fluoroquinoline, m.p, 87.5°-89° C.

ethyl 4-(6,7-dimethoxyquinolin-3-yl)benzoate, m.p. 165°-166° C.

4-phenylpropyl-6,7-dimethoxyquinoline hydrochloride, m.p. 144°-147° C.

3-(thien-3-yl)-5,7-dimethylquinoline, m.p. 109.50°-111° C.

3-(5-chlorothien-2-yl)-6,7-dimethylquinoline, m.p. 131.5°-132.5° C.

3-(3-fluoro-4-methoxyphenyl)-7-methoxy4(1H)-quinolone, m.p. 291°-293° C.

3-(3-fluoro-4-methoxyphenyl)-5,7-dimethylquinoline, m.p. 109°-110° C.

3-(thien-3-yl)-6,7-difluoroquinoline, m.p. 141.5°-143.5° C.

3-benzyloxy-6,7-dimethoxyquinoline, m.p. 146.5°-148.5° C.

3-(2-methoxypyrid-5-yl)-6,7-dimethoxyquinoline, m.p. 170.5°-171.5° C.

3-cyclohexylethyl-6,7-dimethoxyquinoline (oil) (Calc'd/Fnd; C:76.22175.10; H: 8.42/8.30; N: 4.68/4.60)

4- 3-(3-fluorophenyl)quinolin-6-yl!benzoic acid, m.p.>285° C.

2-phenyl-1- 3-(3-fluorophenyl)quinolin-6-yl)ethylene, m.p. 157.5°-159°C.

ethyl-4- 3-(3-fluorophenyl)quinolin-6-yl!benzoate, m.p. 168°-170° C.

methyl-3- 3-(3-fluorophenyl)quinolin-6-yl!propanoate, m.p. 83°-85° C.

methyl-3- 3-(3-fluorophenyl)quinolin-6-yl!propanoate, m.p. 184°-186° C.

3-(3-fluorophenyl)-6-(thien-3-yl)quinoline, m.p. 122°-124° C.

1-phenyl-2- 3-(3-fluorophenyl)quinolin-5-yl!ethylene, m.p. 101°-102° C.

3-(3-fluorophenyl)-6-methoxycarbonylquinoline, m.p. 196°-196.5° C.

3-(3-fluorophenyl)quinoline-6-carboxylic acid, m.p. 283°-284° C.

3-(3-fluorophenyl)-6-(N-ethylaminocarbonyl)quinoline, m.p. 184°-185° C.

1-dimethylamino-3- 3-(3-fluorophenyl)quinolin-6-yl!-2-propyne, m.p.73°-74° C.

N-ethyl-3- 3-(3-fluorophenyl)quinoline-5-yl!propionamide, m.p.147.5°-149.5° C.

4- 3-(3-fluorophenyl)quinolin-5-yl!benzoic acid, m.p.>280° C.

N-ethyl-3- 3-(3-fluorophenyl)quinoline-6-yl!propionamide, m p.141°-142.5° C.

methyl-3- 3-(3-fluorophenyl)quinolin-5-yl!propenoate, m.p. 128°-130° C.

3-(3-fluorophenyl)-5-(thiophen-3-ylquinoline, m.p. 102°-103.5° C.

1-dimethylamino-313-(3-fluorophenyl)quinolin-6-yl!propanedihydrochloride, m.p. 194°-198° C.

1- 3-(3-fluorophenyl)quinolin-6-yl!-1-hexyne hydrochloride, m.p.165°-169° C.

methyl-3- 3-(3-fluorophenyl)quinolin-5-yl!propanoate hydrochloride, m.p.196°-198° C.

ethyl-4- 3-(3-fluorophenyl)quinolin-5-yl!benzoate, m.p. 132°-134° C.

1- 3-(3-fluorophenyl)quinolin-6-yl!n-hexane hydrochloride, m.p.147.5°-149.5° C.

1- 3-(3-fluorophenyl)quinolin-5-yl!-1-hexyne hydrochloride, m.p.168°-170.5° C.

1- 3-(3-fluorophenyl)quinolin-5-yl!-n-hexane hydrochloride, m.p.141°-144° C.

3- 3-(3-fluorophenyl)quinolin-5-yl!propanoic acid, m.p. 249°-251° C.

N-(2-Phenylethyl)-3- 3-(3-fluorophenyl)-quinolin-5-yl!propionamide, m.p.137.5°-140° C.

1-dimethylamino-3- 3-(3-fluorophenyl)quinolin-5-yl!propanedihydrochloride, m.p. 193°-198° C.

1-dimethylamino-3- 3-(3-fluorophenyl)quinolin-5-yl!-2-propanedihydrochloride, m.p. 77°-77.5° C.

3-(3-fluorophenyl)-5-(N-ethylaminocarbonyl)quinoline, m.p. 227°-227.5°C.

3-(3-fluorophenyl)-5-methoxycarbonylquinoline, m.p. 144°-145.5° C.

3-(3-fluorophenyl)quinolin-5-carboxylic acid, m.p. >280° C. (dec)

N-(2-phenylethyl)-3- 3-(3-fluorophenyl)quinolin-6-yl!propionamide, m.p.139.5°-140° C.

3-(3-fluorophenyl)-7-(thien-3-yl)quinoline, m.p. 186°-187.5° C.

3- 3-(3-fluorophenyl)quinolin-6-yl!propanoic acid, m.p. 138.5°-141° C.

ethyl-4- 3-(3-fluorophenyl)quinolin-7-yl!benzoate, m.p. 134°-136° C.

methyl-3- 3-(3-fluorophenyl)quinolin-7-yl!propenoate, m.p. 164°-166° C.

3-(3-fluorophenyl)-7-methoxycarbonylquinoline, m.p. 163.5°-165° C.

1- 3-(3-fluorophenyl)quinolin-7-yl!hexyne hydrochloride, m.p. 183°-185°C.

3-(3-fluorophenyl)quinolin-7-carboxylic acid, m.p. >250° C.

4- 3-(3-fluorophenyl)quinolin-7-yl!benzoic acid hydrochloride, m.p.>250°C.

3-(3-fluorophenyl)-7-(N-ethylaminocarbonyl)quinoline, m.p. 193°-195° C.

N-(2-phenylethyl)-3- 3-(3-fluorophenyl)quinolin-7-yl!propionamide, mp.157°-158.5° C.

3- 3-(3-fluorophenyl)quinolin-7-yl!propanoic acid hydrochloride,m.p.>250° C.

N-ethyl-3- 3-(3-fluorophenyl)quinolin-7-yl!propionamide, mp. 148°-149.5°C.

methyl-3- 3-(3-fluorophenyl)quinolin-7-yl!propanoate, m.p. 111.5°-113°C.

1-dimethylamino-3- 3-(3-fluorophenyl)quinolin-7-yl!propanedihydrochloride, m.p. 225.5°-228° C.

1- 3-(3-fluorophenyl)quinolin-7-yl!-n-hexane hydrochloride, m.p.158°-160° C.

1-dimethylamino-3- 3-(3-fluorophenyl)quinolin-7-yl!-2-propyne, m.p.86.5°-88.5° C.

3-(3-fluorophenyl)-6-carboxamidoquinoline, m.p. 225°-227° C.

5- 3-(3-fluorophenyl)quinolin-6-oxy!pentanoic acid, m.p. 216°-217° C.

3-(3-fluorophenyl)-6- 1 -(1-pyrrolidin-1-yl)-propan-3-yl!quinolinedihydrochloride, m.p. 238°-242° C.

3-(3-fluorophenyl)-7-(1-diethylamino-propan-3-yl)quinolinedihydrochloride, mp. 219°-222° C.

3-(3-fluorophenyl)-7-(1-diethylamino-2-propyn-3-yl)quinoline, m.p.84°-86° C.

3-(3-fluorophenyl)-6-(1-diethylamino-propan-3-yl)quinolinedihydrochloride, m.p. 237°-241° C.

3-(3-fluorophenyl)-6- 1-(1-methylpiperazin-4-yl)propan-3-yl!quinolinetrihydrochloride, m.p. 245°-248° C. (dec)

3-(3-fluorophenyl)-7- 1-(1-methylpiperazin-4-yl)propan-3-yl!quinolinetrihydrochloride, m.p. >280° C.

3-(3-fluorophenyl)-6-(1-diethylamino-2-propyn-3-yl)quinolinedihydrochloride, m.p. 208°-211° C. (dec)

3-(3-fluorophenyl)-7- 1-(morpholin-4-yl)-propan-3-yl!quinolinedihydrochloride, m.p. 190°-193° C. (dec)

3-(3-fluorophenyl)-6- 1-(morpholin-4-yl)-propan-3-yl!quinolinedihydrochloride, m.p. 267°-270° C. (dec)

3-(3-fluorophenyl)-7- 1-(4methylpiperazin-1-yl)-2-propyn-3-yl!quinoline,m.p. 139.5°-141° C.

3-(3-fluorophenyl)-7- 1-(morpholin-4-yl)-2-propyn-3-yl!quinoline, mp.137.5°-140° C. (dec)

3-(3-fluorophenyl)-6- 1-(morpholin-4-yl)-2-propyn-3-yl!quinoline, m.p.134°-136° C. (dec)

3-(3-fluorophenyl)-7- 1-(1-pyrrlidino)-propan-3-yl!quinolinedihydrochloride, m.p. 245°-248° C. (dec)

3-(3 -fluorophenyl)-6- 1-(1-pyrollidino)-2-propyn-3 -yl!quinolinedihydrochloride, m.p. 214°-216° C. (dec)

3-(3-fluorophenyl)-7- 1-(1-pyrollidino)-2-propyn-3-yl!quinoline, m.p.84°-87° C.

3-(3-fluorophenyl)-6- 1-(4-methylpiperazin-1-yl)-2-propyn-3-yl!quinoline, m.p. 132°-134° C.

3- (3-fluorophenyl)-6- 4-(N,N-dimethylamino)butyloxy!quinolinedihydrochloride, m.p. 245°-248° C.

3-(3-fluorophenyl)-6-(1-hydroxy-2-propyn-3-yl)quinoline, m.p. 159°-160°C.

3-(3-fluorophenyl)-6-(4-hydroxy-butoxy)quinoline, m.p. 84°-86° C.

3-(3-fluorophenyl)-6-1-(t-butyldimethylsilyloxy)-2-propyn-3-yl!quinoline, m.p. 100.5°-102° C.

methyl-5- 3-(3-fluorophenyl)quinolin-6-oxy!pentanoate, m.p. 70°-71° C.

3-(3-fluorophenyl)-6-(4-chlorobutoxy)quinoline hydrochloride, m.p.179°-182.5° C.

3-(3-fluorophenyl)-7- (2s)-2,3-dihydroxypropoxy-2-propyn-3-yl!quinolinehydrochloride, m.p. 170°-173° C.

6,7-dimethoxy-3-p-tolyloxyquinoline, m.p. 215°-217° C. (dec)

6,7-dimethoxy-3-phenoxyquinoline, m.p. 224°-226° C.

5,7-dimethoxy-3-phenoxyquinoline, m.p. 201°-203° C.

methyl 3- 3-(3-fluorophenyl)quinolin-6-yl!propenoate, m.p. 184°-186° C.

ethyl 4- 3-(3-fluorophenyl)quinolin-6-yl!benzoate, m.p. 168°-170° C.

2-phenyl-6,7-dimethylquinoxaline, m.p. 128°-131° C.

2-(4-methoxyphenyl)-6,7-dimethoxyquinoxaline hydrochloride, m.p.212°-16° C.

2-(thien-3-yl)-6,7-dimethoxyquinoxaline hydrochloride, mp. 228°-231° C.

2-(thien-3-yl)quinoxaline, m.p. 87.5°-89° C.

2-phenyl-6,7-dimethoxyquinoxaline hydrochloride, m.p. 200° C.

6,7-dimethyl-2-(thien-3-yl)-quinoxaline, m.p. 142°-143.5° C.

2-phenyl-6,7-diethoxyquinoxaline hydrochloride, m.p. 180°-185° C.

2-(4-methoxyphenyl)-6,7-dimethoxyquinoxaline-4-N-oxide, m.p. 224°-226°C.

2-phenyl-6,7-dimethoxyquinoxaline-4-N-oxide, m.p. 219°-222° C.

2-phenyl-6,7-dimethylquinoxaline, m.p. 128°-131° C.

2-phenyl-6,7-dichloroquinoxaline, m.p. 158°-160° C.

2-phenyl-6,7-dimetoxyquinoxaline, m.p. 200° C.

2-phenyl-6,7-diethoxyquinoxaline, m.p. 180°-185° C.

2-phenethyl-6,7-diethoxyquinoxaline, m.p. 148°-155° C.

2-(thien-3-yl)-6,7-dimethylquinoxaline, m.p. 142°-143.5° C.

2-(thien-3-yl)-6,7-diethoxyquinoxaline, mp. 217°-224° C.

2-(5-chlorothien-2-yl)-6,7-diethoxyquinoxaline, m.p. 189°-194° C.

2-(5-chlorothien-2-yl)-6,7-dimethoxyquinoxaline, m.p. 218°-225° C.

2-(5-fluorothien-2-yl)-6,7-diethoxyquinoxaline,

2-(thien-2-yl)-6,7-diethoxyquinoxaline,

2-(thien-2-yl)-6,7-dimethoxyquinoxaline, m.p. 214°-220° C.

2-(thien-2-yl)-6,7-dicarboxyquinoxaline,

6,7-dimethyl-2- 4-1-tetrazol-5-yl)phenyl!quinoxaline, m.p. 278°-280° C.(dec.)

6,7-dimethyl-2- 5-(5-chloro-2-thien-2-yl)-2-thienyl!quinoxaline, m.p.180°-183° C.

6,7-dimethyl-2- 5-(5-chloro-2-thien-2-yl)-2-thienyl!quinoxaline, m.p.174°-177° C.

6,7-dimethyl-2- 4-(1-methyl-tetrazol-5-yl)phenyl!quinoxaline, m.p.235°-238° C.

2-(3-fluoro-4-methoxy-phenyl)-7-(4-pyridyl)quinoxaline, m.p. 173°-175°C.

2-(3-fluoro-4-methoxy-phenyl)-6-(-pyrid-4-yl)quinoxaline, m.p. 210°-216°C.

2-(5-chloro-2-thien-2-yl)-7-(4-pyridyl)quinoxaline, m.p. 214°-215° C.

2-(5-chloro-2-thien-2-yl)-6-(pyrid-4-yl)quinoxaline, m.p. 260°-263° C.

7-(4-pyridyl-2-(3-thien-3-yl)quinoxaline, m.p. 210°-212° C.

6-(pyrid-4-yl)-2-(3-thienyl)quinoxaline, m.p. 234°-236° C.

2-(3-chloro-4methoxyphenyl)pyrido 3,4-b!pyrazine,

3-5-chlorothien-2-yl)pyrido 2,3-b!pyrazine, m.p. 194°-196° C.

2-3-fluoro-4-methoxyphenyl)pyrido 3,4-b!pyrazine, m.p. 214°-216° C.

2-3,4-dimethoxyphenyl)pyrido 3,4-b!pyrazine, m.p. 124°-127° C.

2-5-chlorothien-2-yl)pyrido 3,4-b!pyrazine, m.p. 203°-206° C.

2-(thien-2-yl)pyrido 3,4-b!pyrazine,

2-(thien-3-yl)pyrido 3,4-b!pyrazine,

2-(5-chlorothien-3-yl)pyrido 3,4-b!pyrazine,

2-(3-fluoro4-methoxyphenyl)thienyl 3,4-b!pyrazine, m.p. 187°-189° C.

3-(3'-thien-3-yl)-7-methoxy-pyrido-2,3b)-pyrazine, m.p. 215°-220° C.

7-(3'-thien-3-yl)pyrido-(2,3b)-pyrazine, m.p. 171°-173° C.

7-(3'-thien-3-yl)-2,3-dimethylpyrido-(2,3b)-pyrazine, m.p. 200°-205° C.(dec)

3-(3'-thien-3-yl)-7-bromo-pyrido-2,3b)-pyrazine, m.p. 205°-206.5° C.

2-(3,4-dimethoxyphenyl)pyrido 3,4-b!pyrazine, m.p. 124°-127° C.

3-(5-chloro-2-thien-2-yl)pyrido 2,3-b!pyrazine, m.p. 194°-196° C.

3-(3-fluoro-4-methoxyphenyl)pyrido 2,3-b!pyrazine, m.p. 217°-219° C.

2-(3-fluoro-4-methoxypehenyl)pyrido 3,4-b!pyrazine, m.p. 214°-216° C.

2-(5-chloro-2-thien-2-yl)pyrido 3,4-b!pyrazine, m.p. 203°-206° C.

6,7-dimethoxy-4-naphthalen-2-ylethynylquinazoline, m.p. 158°-161° C.

4-(4-hydroxyphenyl)-6,7-dimethoxyquinazolinehydrochloride, m.p.>270° C.(dec)

4-(naphthalen-1-yl)-6,7-dimethoxyquinazoline, m.p. 144°-147° C.

4-(naphthalen-2-yl)-6,7-dimethoxyquinazoline, m.p. 115°-118° C.

4-phenylacetylenyl-6,7-dimethoxyquinazoline, m.p. 146°-148° C.

4-(3-fluoro-4-methoxyphenyl)-6,7-dimethoxyquinazoline, m.p. 207°-210° C.

4-(3-phenylphenyl)-6,7-dimethoxyquinazoline, m.p. 160°-163° C.

4-(2-phenylethylenyl)-6,7-dimethoxyquinazoline, m.p. 168°-169° C.

4-(2-methoxypyridin-5-yl)-6,7-dimethoxyquinazoline, m.p. 175°-176° C.

4-(1-benzyl-indol-3-yl)-6,7-dimethoxyquinazoUne, m.p. 148°-150° C.

4-(indol-3-yl)-6,7-dimethoxyquinazoline, m.p.>240° C. (dec)

4-(1-methylindol-3-yl)-6,7-dimethoxyquinazoline hydrochloride, m.p.>230°C. (dec)

4-(1-methylsulphonylindol-3-yl)-6,7-dimethoxyquinazoline, m.p.>220° C.(dec)

4-(4-phenylpiperidin-1 -yl)-6,7-dimethoxyquinazoline, m.p. 150°-151° C.

4- 4-(3-chlorophenyl)piperazin-1-yl!-6,7-dimethoxyquinazoline, m.p.155°-156° C.

4-(N-methyl-3,4,5-trimethoxyanilino)-6,7-dimethoxyquinazoline, m.p.149°-151° C.

(+-)-4-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazolinehydrochloride, m.p. 198°-201° C. (dec)

4-(1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazolinehydrochloride, m.p. 195°-197° C. (dec)

4-(N-methyl-4-methoxy-anilino)-6,7-dimethoxyquinazoline hydrochloride,m.p. 202°-265° C.

4-(N-methyl-4-chloro-anilino)-6,7-dimethoxyquinazoline hydrochloride,m.p. 220°-222° C.

4-(2,3-dihydroindol-1-yl)-6,7-dimethoxyquinazoline hydrochloride, m.p.226°-229° (dec)

(6,7-dimethoxyquinazolin4-yl)methyl-(3-trifluoromethylphenyl)aminehydrochloride, m.p. 240°-243° C.

(3-chlorophenyl)-(6,7-dimethoxyquinazolin-4-yl)methylaminehydrochloride, m.p. 235°-237° C.

(3-chlorophenyl)methylquinazolin-4-yl-amine hydrochloride, m.p.233°-235° C.

6,7-dimethoxy-4-naphthalen-1-yl-ethynylquinazoline, m.p. 175°-177° C.

4-(thien-3-yl)-6,7-dimethoxyquinazoline, m.p. 148.5°-151.5° C.

4-benzyl-6,7-dimethoxyquinazoline, m.p. 122.5°-125° C.

2-(4-methylphenyl)-3-methyl-4(3H)quinazolinone, m.p. 139°-141° C.

2-(4-methoxyphenyl)quinazolin-4(3H)-one, m.p. 244°-247° C.

2-(4-methoxyphenyl)-6,7-dimethoxyquinazolin-4(3H)-one, m.p. 288°-291° C.

(6,7-dimethoxyquinazolin-4-yl)-5-indazol-5-yl hydrochloride, m.p.261°-263° C. (dec)

N-phenyl-N-(6,7,8-trimethoxyquinazolin-4-yl)methylamine, m.p.122.5°-124.5° C.

(6,7-dimethoxyquinazolin-4-yl)-N-phenylethylamine hydrochloride, m p.227°-230° C. (dec)

benzyl-(6,7-dimethoxyquinazolin-4-yl)phenylamine hydrochloride, m.p.269°-271 ° C.

(6-chloroquinazolin-4-yl)methylphenylamine, m.p. 106°-108° C.

(3-chloro-phenyl)-(6,7-dimethoxyquinazolin-4-yl)ethylaminehydrochloride, m.p. 261°-263° C.

(6,7-dimethoxyquinazolin-4-yl)methyl-p-tolyl-amine hydrochloride, m.p.230°-234° C. (dec)

benzyl-(6,7-dimethoxyquinazolin-4-yl)amine, m.p. 220°-225° C.

(4-methoxybenzyl)-(6,7-dimethoxyquinazolin-4-yl)amine, m.p. 194°-198° C.

(3,5-dimethoxybenzyl)-(6,7-dimethoxyquinazolin-4-yl)amine hydrochloride,m.p. 265°-269° C.

4-(3,4,5-trimethoxyphenyl)-6,7-dimethoxyquinazoline, m.p. 228°-232° C.

methylphenyl-(9H-purin-6-yl)amine, m.p. 229°-232° C.

(quinazolin-4-yl)-N-phenylmethylamine hydrochloride, m.p. 242°-246° C.(dec)

(6,8-dimethylquinazolin-4-yl)-N-phenylmethylamine, m.p. 120°-121° C.

(6,7-dimethoxyquinazolin-4-yl)-4-morpholin-4-yl-phenyl)aminehydrochloride, m.p. 231°-235° C. (dec)

4-(3-methoxythiophenoxy)-6,7-dimethoxyquinazoline, m.p. 139.5°-141.5° C.

4- N-(indan-5-yl)amino!-6,7-dimethoxyquinazoline hydrochloride, m.p.244°-246° C. (dec)

3-chlorophenyladenine hemi-hydrochloride, m.p. >260° C.

4-(3-chlorothiophenoxy)-6,7-dimethoxyquinazoline, m.p. 152°-153.5° C.

4-(3-aminopyrazolyl)-6,7-dimethoxyquinazoline hydrochloride, m.p.262°-264° C. (dec)

4-(3,6-dioxananilino)-6,7-dimethoxyquinazoline hydrochloride, m.p.267°-269° C. (dec)

N⁶ -(3,4,5-dimethoxyphenyl)adenine hydrochloride, m.p.>250° C.

6,7-dimethoxy-4-(α-naphthylamino)quinazoline hydrochloride, m.p.>250° C.

6,7-dimethoxy-4-(β-naphthylamino)quinazoline hydrochloride, m.p.>250° C.

4-(cyclohexylanilino)-6,7-dimethoxyquinazoline, m.p. 239°-244° C.

4-(3,4,5-trimethoxyanilino)-6,7-dimethoxyquinazoline hydrochloride, m.p.260°-265° C.

6,7-dimethoxy-4-(N-methylanilino)quinazoline hydrochloride, m.p.>230° C.

4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline, m.p. 152°-153° C.

(4-methoxyphenyl)methyl-(1H-pyrazolo 3,4-d!pyrimidin-4-yl)aminehydrochloride, m.p. 223°-226° C.

6-(thien-3-yl)-1,8-naphthyridin-2(1H)-one, m.p. 250°-250° C.

6-(4-methoxyphenyl)-1,8-naphthyridin-2(1H)-one, m.p. 251°-253° C.

7-(3,4-dimethoxyphenyl)pteridine, m.p. 198°-199° C.

7-(4-methoxyphenyl)pteridine, m.p. 210°-213° C.

7-(5-chloro-2-thien-2-yl)pteridine, m.p. 231 ° C. (dec)

7-(3-fluoro-4-methoxy-phenyl)pteridine

7-(5-chlorothien-2-yl)pteridine, m.p. 231° C. dec.),

7-(thien-2-yl)pteridine

5,6-dimethoxy-2-(2-phenylethenyl)benzothiazole, m.p. 133°-135° C.

methyl-(1H-pyrazole3,4-d!pyrimidin-4-yl)-(3-trifluoromethylphenyl)amine, m.p. 226°-227° C.

3-benzyl-5-(thien-3-yl)pyridine, m.p. 81°-82° C.)

3-(thien-3-yl)-6,7-dimethoxyisoquinoline-N-oxide, m.p. 197°-200° C.

3-(thien-3-yl)-6,7-dimethoxyisoquinoline-N-oxide, m.p. 197°-200° C.

3-(thien-3-yl)-6,7-dimethoxy-1(2H)-isoquinolone, m.p. 213°-216° C.

4-(thien-3-yl)isoquinoline hydrochloride, m.p. 179°-183° C.

4-(4-methoxyphenyl)isoquinoline hydrochloride, m.p. 196°-199° C.

2-phenyl-6,7-dimethoxy-4H-3,1-benzoxazin-4-one, m.p. 198°-201° C.

3-(4-methoxyphenyl)-7-methoxy-1-naphthalenol, m.p. 155°-159° C.

1-phenylphthalazine, m.p. 139.5°-141° C.

(4-methoxyphenyl)methyl-(1H-pyrazolo 3,4-d!pyrimidin-4-yl)aminehydrochloride, m p. 223°-226° C.

EXAMPLE 39

The procedures described in the above examples may be followed toprepare the following representative compounds If TABLE XI.

TABLE XI

5-(6,7-Dimethoxy-quinolin-3-yl)-2-hydroxy-benzoic acid

5-(6,7-Dimethoxy-quinolin-3-yl)-2-methoxy-benzoic acid

5-(6,7-Dimethoxy-quinolin-3-yl)-2-methoxy-benzamide

5-(6,7-Dimethoxy-quinolin-3-yl)-2-hydroxy-benzamide

4-(6,7-Dimethoxy-quinolin-3-yl)-2-hydroxy-benzoic acid

8-Fluoro-6,7-dimethoxy-3-(4-methoxy-phenyl)-quinoline

N-(6,7-Dimethoxy-quinolin-4-yl)-N-phenyl-methylamine

N-(6,7-Dimethoxy-quinolin-4-yl)-aniline

5-(6,7-Dimethoxy-quinolazolin-4-yl)-2-hydroxy-benzoic acid

2-Benzyloxy-5-(6,7-dimethoxy-quinazolin-4-yl)-benzoic acid

5-(6,7-Dimethoxy-quinolazolin-4-yl)-2-methoxy-benzoic acid

5-(6,7-Dimethoxy-quinolazolin-4-yl)-2-hydroxy-benzamide

5-(6,7-Dimethoxy-quinolazolin-4-yl)-2-hydroxy-benzamide

4-(6,7-Dimethoxy-quinolazolin-4-yl)-2-hydroxy-benzoic acid

6,7-dimethoxy-4-(1-naphthylthio)-quinazoline

6,7-dimethoxy-4-(2-naphthylthio)-quinazoline

6,7-dimethoxy-4-(1-naphthyloxy)-quinazoline

6,7-dimethoxy-4-(2-naphthyloxy)-quinazoline

6,7-Dimethoxy-quinolazolin-4-yl)-2-naphthyl-ethylamine

6,7-dimethoxy-4-(naphthalene-2-sulfinyl)-quinazoline

6,7-dimethoxy-4-(naphthalene-2-sulfonyl)-qinazoline

4-(4-Methoxyphenyl)-7,8-dimethoxyisoquinoline

4-(3-Fluoro-4-methoxyphenyl)-7-chloroisoquinoline

4-(3-Fluoro-4-methoxyphenyl)-8-chloroisoquinoline

1-Anilinoisequinoline

1-(N-Methyl-3,4,5-trimethoxyanilino)isoquinoline

Preparation of Pharmaceutical Compositions and Pharmacological TestSection

Compounds within the scope of this invention exhibit significantactivity as protein tyrosine kinase inhibitors and possess therapeuticvalue as cellular antiproliferative agents for the treatment of certainconditions including psoriasis, atherosclerosis and restenosis injuries.It is expected that the invention will be particularly applicable to thetreatment of atherosclerosis. With regard to the treatment of someconditions, for example, atherosclerosis, certain people may beidentified as being at high risk, for example, due to genetic,environmental or historical factors. Compounds within the scope of thepresent invention exhibit the modulation and/or inhibition of cellsignaling, cell proliferation, cell inflammatory response, the controlof abnormal cell growth and cell reproduction can and can be used inpreventing or delaying the occurrence or reoccurrence of such conditionsor otherwise treating the condition.

To determine the effectiveness of compounds of this invention, thefollowing pharmacological tests described below, which are accepted inthe art and recognized to correlate with pharmacological activity inmammals, are utilized. Compounds within the scope of this invention havebeen subjected to these various tests, and the results obtained arebelieved to correlate to useful cellular antiproliferative activity. Thebelow described tests are useful in determining the EGF receptor kinase,PDGF receptor kinase and insulin receptor kinase inhibition activitiesof compounds disclosed herein. The results of these tests are believedto provide sufficient information to persons skilled in thepharmacological and medicinal chemistry arts to determine the parametersfor using the studied compounds in one or more of the therapiesdescribed herein.

EGF-Receptor Purification

EGF-receptor purification is based on the procedure of Yarden andSchlessinger. A431 cells are grown in 80 cm² bottles to confluency(2×10⁷ cells per bottle). The cells are washed twice with PBS andharvested with PBS containing 11.0 mmol EDTA (1 hour at 37° C., andcentrifuged at 600g for 10 minutes. The cells arc solubilized in 1 mlper 2×10⁷ cells of cold solubilization buffer (50 mmol Hepes buffer, pH7.6, 1% Triton X-100, 150 mmol NaCl, 5 mmol EGTA, 1 mmol PMSF, 50 μg/mlaprotinin, 25 mmol benzamidine, 5 μg/ml leupeptic, and 10 μg/ml soybeantrypsin inhibitor) for 20 minutes at 4° C. After centrifugation at100,000 g for 30 minutes, the supernatant is loaded onto a WGA-agarosecolumn (100 μl of packed resin per 2×10⁷ cells) and shaken for 2 hoursat 4° C. The unabsorbed material is removed and the resin washed twicewith HTN buffer (50 mmol Hepes, pH 7.6, 0.1% Triton X-100, 150 mmolNaCl), twice with HTN buffer containing 1M NaCl, and twice with HTNGbuffer (50 mmol Hepes, pH 7.6, 0.1% Triton X-100, 150 mmol NaCl, and 10%glycerol). The EGF receptor is eluted batchwise with HTNG buffercontaining 0.5M N-acetyl-D-glucosamine (200 μl per 2×10⁷ cells.). Theeluted material is stored in aliquots at -70° C. and diluted before usewith TMTNG buffer (50 mmol Tris-Mes buffer, pH 7.6, 0.1% Triton X-100,150 mmol NaCl, 10% glycerol).

ATP and EGF Dependence of Autophosphorylation

WGA-purified EGF receptor from A431 cells (0.5 μg/assay is activatedwith EGF (0.85 μM) for 20 minutes at 4° C.. The assay is performed at15° C. and initiated by addition of Mg(Ac)₂ (60 mmol), Tris-Mes buffer,pH 7.6 (50 mmol), ³² P!ATP (carrier free, 5 μCi/assay), and increasingconcentrations of nonradioactive ATP. The assay is terminated after10-sec by addition of SDS sample buffer. The samples are run on a 6% SDSpolyacrylamide gel. The gel is dried and autoradiographed as describedabove. The relevant radioactive bands are cut and counted in theCerenkov mode. The Km for ATP determined in this fashion is found to be7.2 μ(M. With use of the 10-sec assay protocol, the EGF concentrationdependence of EGF-RK autophosphorylation is determined.

Inhibition of EGF-R Autophosphorylation

A431 cells were grown to confluence on human fibronectin coated tissueculture dishes. After washing 2 times with ice-cold PBS, cells werelysed by the addition of 500 μl/dish of lysis buffer (50 mmol Hepes, pH7.5,150 mmol NaCl, 1.5 mmol MgCl₂, 1 mmol EGTA, 10% glycerol, 1% tritonX-100, 1 mmol PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin) and incubating5 minutes at 4° C. After EGF stimulation (500 μg/ml 10 minutes at 37°C.) immunoprecipitation was performed with anti EGF-R (Ab 108) and theautophosphorylation reaction (50 μl aliquots, 3 μCi γ-³² P!ATP) samplewas carried out in the presence of 2 or 10 μM of compound of the presentinvention, for 2 minutes at 4° C. The reaction was stopped by adding hotelectrophoresis sample buffer. SDA-PAGE analysis (7.5% els) was followedby autoradiography and the reaction was quantitated by densitometryscanning of the x-ray films.

In order to test the present compounds for selective inhibition, theprocedure is repeated using PDGF stimulation in place of EGFstimulation. "IC₅₀," as used below refers to the concentration ofinhibitor mM) at which the rate of autophosphorylation is halved,compared with media containing no inhibitor.

Inhibition of PDGF-R Autophosphorylation

Lysate from NIH 3T3 cells was diluted one-third in Triton-free bufferand stimulated with 10 ng/ml PDGF for 30 minutes at 4° C. The equivalentof 1/15 of a 175-cm² plate of lysate was used per sample. The stimulatedlysate was then immunoprecipitated with rabbit polyclonalanti-PDGF-receptor antibodies raised against a synthetic peptide fromthe COOH-terminal region (amino acids 1094-1106) or the humanPDGF-receptor B-subunit and added to increasing concentrations of testcompound of the present invention. After 10 minutes at 4° C., 10 μCi ofγ-³² P!ATP were added and further incubated for 10 minutes at 4° C.Samples were separated by SDS-PAGE on 6% gels.

Inhibition of Cell Proliferation as Measured by Inhibition Of DNASynthesis

EGF receptor overexpressing (HER14) cells were seeded at 1×10⁵ cells perwell in 24-well Costar dishes pre-coated with human fibronectin (byincubating for 30 minutes at room temperature with 10 μg/0.5 ml/well).The cells were grown to confluence for 2 days. The medium was changed toDMEM containing 0.5 calf serum for 36-48 hours and the cells were thenincubated with EGF (Toyobo, New York, N.Y.) (20 ng/ml), PDGF (Amgen) (20ng/m 1) or serum (10% calf serum, FCS) and different concentrations ofthe compound of the present invention. 3H! thymidine, (NEN, Boston,Mass.) was added 16-24 hours later at 0.51 μCi/ml for 2 hours. TCAprecipitable material was quantitated by scintillation counting (CResults of this assay are determined. "IC₅₀ " of the concentration ofinhibitor (nM) at which ³ H! thymidine incorporation is halved, comparedwith media containing no buffer is calculated As FCS contains a broadrange of growth factors, the IC₅₀ values for PDGF should be lower thanfor FCS, indicating that the compounds of the present invention do notact as general inhibitors.

These results indicate that compounds within the scope of the inventioninhibit the EGF and/or PDGF growth factor receptors selectively.

Cell Culture

Cells termed HER 14 and K721A (=DK) were prepared by transfecting NIH3T3cells (clone 2.2) (From C. Fryling, NCl, NIH), which lack endogenousEGF-receptors, with cDNA constructs of wild-type EGF-receptor or mutantEGF-receptor lacking tyrosine kinase activity (in which Lys 721 at theATP-binding site was replace by an Ala residue, respectively). All cellswere grown in DMEM with 10% calf serum (Hyclone, Logan, Utah).

Further tests which show the effectiveness and selectivity of compoundsof this invention to inhibit cell proliferation are as follows.

CSF-1R CELL-FREE AUTOPHOSPHORYLATION ASSAY

For a regular 28 tube assay (14 samples per 15 well gel):

In 2 ml eppendorf tube: 140 mg protein A sepharose (5 mg/sample)

Swell in 20 mM Hepes pH 7.5 and wash 2× in Hepes

Add 280 λα-CSF-1R (from rabbit 3: C1-3-?)

20 min RT shaking

Wash 3× in HNTG pH 7.5:20 mM Hepes

150 mM NaCl

0.1% triton X-100

10 % glycerol

In 15 ml tube: 2.8 ml lysate (100 λ/sample of lysate made fromunstarved, subconfluent cfm Y cells)

lysis buffer: 20 mM Hepes

1.5 mM MgCl₂

150 mM NaCl

1 mM EGTA

10% glycerol

1% triton X-100

Protease inhibitors added fresh:

PMSF: 8 mg/ml-2500× in 100% EtOH, store frozen, add 100λ/10 ml lysisbuffer Aprotinin: 10 mg/ml=250× in H₂ O, store frozen (expires in about6 months), add 40λ/10 ml lysis buffer

Leupeptin: 1 mg/ml=250× in H₂ O, store frozen (expires in about 6months), add 40λ/10 ml lysis buffer

Add washed beads to stimulated lysate and incubate 90 min 4° C. onrotator or shaking (anywhere from 1 to 2.5 hours OK)

Meanwhile:

prepare 28 compound tubes:

make 40 mM solutions of compounds in 100% DMSO

make serial dilutions in 50 mM Tris pH 7.5+10 mM MnCl₂

aliquot 10λ compound solution into each I ml eppendorf reaction tubewaiting on ice, control blanks get 10λ buffer

Wash beads 1× HNTG, 2×10 mM Tris pH 7.5 (can transfer beads to 2 mleppendorf tube for washing)

Remove all liquid with gel loading pipette tip or Hamilton syringe

Add back 560λ 50 mM Tris pH 7.5+10 mM MnCl₂ (20λ/sample)

Dole out into waiting reaction tubes (approx. 28λ/tube using large boretip)

Vortex, incubate 10 min on ice

Add 10λ ATP solution: 312λ 50 mM Tris pH 7.5+10 mM MnCl₂

2.7λ cold ATP (stock of 10 mM in 50 mM

Tris=20 μM final)

351 ³² P-ATP (10 μCi/sample)

Vortex, incubate 10 min on ice

Add 45λ 2× SDS-sample buffer, heat 95° C. 6 min

7.5% SDS-PAGE, fix, dry, expose (usually 4 hrs)

*Note: it is important to keep lysate cold at all times: when thawing,don't use water which is too warm and use cold buffer for wash steps.

Ick Kinase: Immunoprecipitated from Jurkat lysate.⁵.6

A. Jurkat cells (human T-cell leukemia, ATCC clone #E6-1) were grown insuspension in RPMI 1640 medium with 10% fetal calf serum, 100 U/mlpenicillin/streptomycin, and 2 mM L-glutamine in a 37° C. incubator at5% CO₂.

B. Cells were grown to 1-1.5×10⁶ cells/ml media, pelleted bycentrifugation, and lysed in lysis buffer at 10⁸ cells/ml buffer (50 mMtris (pH 8), 150 mM NaCl, 5 mM EDTA, 10% glycerol, and 1% NP-40, towhich fresh protease and phosphatase inhibitors were added as describedabove for A431 lysate). Lysates stored at -70° C.

C. Immunoprecipitation #5264:12!: 3-4 mg Protein-A sepharose/samplewashed 2×20 mM Hepes (pH 7.5). 1 ul α-lck antibody (prepared aspolyclonals in rabbits using a peptide antigen corresponding to theN-terminal region of human lck) per sample added to the Protein-A andshaken 20 min at room temperature. After washing 3× HNTG, lysate from2×10⁶ cells was added to each sample, rotated 2 hr at 4° C., then washed3× HNTG (2nd wash containing 0.5 N NaCl). If all samples containidentical concentrations of the enzyme, then the immuno-precipitationcan be done in bulk and alloquoted to appropriate numbers of tubes priorto assay set-up.

D. Compound screening in the cell-free/ck kinase assay #5264:12!: RPRcompounds (40 mM stocks in DMSO) were initially screened atconcentrations of 10 and 100 uM in samples containing Ickimmuno-precipitated from 2×10⁶ cells, 5 uM cdc2 (a p34^(cdc2) -derivedsynthetic peptide (N6-20) prepared by R. Howk, RPR)⁷, 5 mM MnCl₂, 5 uMATP and 30 uCi g³² p-ATp (6000Ci/mmol, NEN) in 20 mM hepes (pH 7.5) for5 min at 30° C. Samples were analyzed by 5-15% SDS-PAGE andautoradiography as described for EGFR kinase assays.

E. Intact cell activation/inhibition studies⁸,9 #5264:31!:˜5×10⁷ cellsper sample in 1 ml media were activated with either 10 ug a-CD3 (cloneCris 7, Biodesign) for 1 min at 37° C. or 20 ng PMA and 10 ug PHA for 20min at 37° C. in the presence and absence of compound (added earlier sothat the total time of compound incubation is 30 min). Incubations wereterminated by centrifugation and lysis (as described). Samples wereanalyzed by immunoprecipitation (aPY (100 ul/10⁸ cells), a-PLC (100ul/10⁸ cells), or azeta (20 ul/10⁸ cells)), followed by SDS-PAGE andwestern blotting onto nitrocellulose and inimunoblotting using RC20recombinant aPY-HRP Transduction Labs) and ECL (Amersham).

cAMP-dependent Protein Kinase (PKA) Assay¹⁰

Selectivity assay for compounds is performed as follows. Each samplecontains 0.4 pmolar units PKA (from rabbit muscle, Sigma), 1 uM cAMP, 50uM Tris-HCL (pH7), 10 mM MgAc, 50 ug BSA, 16 uM Kemptide substrate(specific cAMP kinase phosphate acceptor whose sequence corresponds tothe pig liver pyruvate kinase phosphorlyation site), 16 uM ATP, 16 uCi³² P-ATP (6000Ci/mmol, NEN), +/- compound and dH₂ O to a final volume of200 ul. Reactions proceed for 5 min. at 30° C., and are terminated bythe addition of 100 ul 375 mM H₃ PO₄. 50 ul each sample spotted ontoWhatman P81 phosphocellulose filters, which are washed 3× (15 min.) in75 mM H₃ PO₄, followed by an acetone rinse and dry (Cerenkov) counting.

In view of the results of the above test, compounds of the presentinvention can be shown to be selective.

The preferred class of compounds exhibiting CSF-1 inhibition and lckKinase inhibition are the 6,7-dialkoxy quinazolines, and most preferredare the 4-arylamino, 6,7-dimethoxyquinazolines. The most preferred lckinhibitory compound is4-(3,4,5-trimethoxyphenylamino)-6,7-dimethoxyquinazoline, (m.p.260°-265° C. (HCl)), which is prepared according to the proceduredescribed in Example 36 using 1.6 g of 3,4,5-trimethoxyaniline and 0.2gof 4-chloro,-6,7-dimethoxyquinazoline, under similar reactionconditions. The most preferred CSF-1 inhibitory compound is 4-(N-methyl,N-phenylamino)-6,7-dimethoxyquinazoline, (m.p>230° C.(HCl)), which isprepared according to the procedure described in Example 36 using 140mgof N-methylaniline and 300 mg of 4-chloroquinazoline, under similarreaction conditions.

The following tables show examples of representative compounds of thisinvention and their test results as determined by the above inhibitionof PDGF-R cell-free autophosphorylation procedure.

    __________________________________________________________________________                                     Inhibition of PDGF-R                                     cell-free Autophosphorylation    COMPOUND                         IC.sub.50 (μM)    __________________________________________________________________________    1 #STR20##                       0.003-0.015    2 #STR21##                       0.050-0.10    3 #STR22##                       0.007    4 #STR23##                       0.2-1    5 #STR24##                       0.06-0.08    6 #STR25##                       1.0-2.0    7 #STR26##                       0.015    8 #STR27##                       15-20    9 #STR28##                       0.02    0 #STR29##                       0.01    1 #STR30##                       0.030-0.070    2 #STR31##                       0.02-0.08    3 #STR32##                       0.05-0.1    4 #STR33##                       0.005-0.030    5 #STR34##                       0.02-0.05    6 #STR35##                       0.7-1.0    7 #STR36##                       0.7-1.0    8 #STR37##                       0.04    9 #STR38##                       0.010-0.060    0 #STR39##                        7-12    1 #STR40##                       0.015    2 #STR41##                       15-20    3 #STR42##                       0.005-0.030    4 #STR43##                       0.04    5 #STR44##                       0.010-0.060    6 #STR45##                        7-12    7 #STR46##                       0.015    8 #STR47##                       15-20    9 #STR48##                       0.005-0.030    0 #STR49##                       0.02-0.05    1 #STR50##                       0.7-1.0    2 #STR51##                       0.7-1.0    3 #STR52##                       0.04    4 #STR53##                       0.010-0.060    5 #STR54##                        7-12    6 #STR55##                       >50    7 #STR56##                       10-20    8 #STR57##                       0.025-0.3    9 #STR58##                       0.05-0.2    0 #STR59##                       >50    1 #STR60##                       >50    2 #STR61##                       0.5-3    3 #STR62##                       9    4 #STR63##                       7    5 #STR64##                       0.6    6 #STR65##                       0.25    7 #STR66##                       2    8 #STR67##                       2    9 #STR68##                       <2    0 #STR69##                       <2    __________________________________________________________________________    4-Substituted-6,7-di-methoxyquinazolines                               EGF-R                                   PDGF-R    __________________________________________________________________________    1 #STR70##                 0.02                                   1.5    2 #STR71##                 0.1 >50    3 #STR72##                 2    4 #STR73##                 4.0 15    5 #STR74##                 --  25    6 #STR75##                 0.35                                   15    7 #STR76##                 --  5-20    8 #STR77##                 <1.0                                   >20    9 #STR78##                 0.050                                   10    0 #STR79##                 0.010                                   20    __________________________________________________________________________

The results obtained by the above experimental methods evidence theuseful protein tyrosine kinase inhibition properties of compounds withinthe scope of the present invention and possess therapeutic value ascellular antiproliferative agents. The above pharmacological testresults may be used to determine the dosage and mode of administrationfor the particular therapy sought.

The compounds of the present invention can be administered to amammalian host in a variety of forms adapted to the chosen route ofadministration, i.e., orally, or parenterally. Parenteral administrationin this respect includes administration by the following routes:intravenous, intramuscular, subcutaneous, intraocular, intrasynovial,transepithelial including transdermal, ophthalmic, sublingual andbuccal; topically including ophthalmic, dermal, ocular, rectal and nasalinhalation via insufflation and aerosol and rectal systemic.

The active compound may be orally administered, for example, with aninert diluent or with an assimilable edible carder, or it may beenclosed in hard or soft shell gelatin capsules, or it may be compressedinto tablets, or it may be incorporated directly with the food of thediet. For oral therapeutic administration, the active compound may beincorporated with excipient and used in the form of ingestible tablets,buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers,and the like. Such compositions and preparations should contain at least0.1% of active compound. The percentage of the compositions andpreparations may, of course, be varied and may conveniently be betweenabout 2 to about 6% of the weight of the unit. The amount of activecompound in such therapeutically useful compositions is such that asuitable dosage will be obtained. Preferred compositions or preparationsaccording to the present invention are prepared so that an oral dosageunit form contains between about 1 and 1000 mg of active compound.

The tablets, troches, pills, capsules and the like may also contain thefollowing: A binder such as gum tragacanth, acacia, corn starch orgelatin; excipients such as dicalcium phosphate; a disintegrating agentsuch as corn starch, potato starch, alginic acid and the like; alubricant such as magnesium stearate; and a sweetening agent such assucrose, lactose or saccharin may be added or a flavoring agent such aspeppermint, oil of wintergreen, or cherry flavoring. When the dosageunit form is a capsule, it may contain, in addition to materials of theabove type, a liquid carrier. Various other materials may be present ascoatings or to otherwise modify the physical form of the dosage unit.For instance, tablets, pills, or capsules may be coated with shellac,sugar or both. A syrup or elixir may contain the active compound,sucrose as a sweetening agent, methyl and propylparabens aspreservatives, a dye and flavoring such as cherry or orange flavor. Ofcourse, any material used in preparing any dosage unit form should bepharmaceutically pure and substantially non-toxic in the amountsemployed. In addition, the active compound may be Incorporated intosustained-release preparations and formulations.

The active compound may also be administered parenterally orintraperitoneally. Solutions of the active compound as a free base orpharmacologically acceptable salt can be prepared in water suitablymixed with a surfactant such as hydroxypropylcellulose. Dispersion canalso be prepared in glycerol, liquid polyethylene glycols, and mixturesthereof and in oils. Under ordinary conditions of storage and use, thesepreparations contain a preservative to prevent the growth ofmicroorganisms.

The pharmaceutical forms suitable for injectable use include sterileaqueous solutions or dispersions and sterile powders for theextemporaneous preparation of sterile injectable solutions ordispersions. In all cases the for must be sterile and must be fluid tothe extent that easy syringability exists. It may be stable under theconditions of manufacture and storage and must be preserved against thecontaminating action of microorganisms such as bacteria and fungi. Thecarrier can be a solvent or dispersion medium containing, for example,water, ethanol, polyol (for example, glycerol, propylene glycol, andliquid polyethylene glycol, and the like), suitable mixtures thereof,and vegetable oils. The proper fluidity can be maintained, for example,by the use of a coating such as lecithin, by the maintenance of therequired particle size in the case of dispersion and by the use ofsurfactants. The prevention of the action of microorganisms can bebrought about by various antibacterial and antifungal agents, forexample, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, andthe like. In many cases, it will be preferable to include isotonicagents, for example, sugars or sodium chloride. Prolonged absorption ofthe injectable compositions can be brought about by use of agentsdelaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the activecompound in the required amount in the appropriate solvent with variousof the other ingredients enumerated above, as required, followed byfiltered sterilization. Generally, dispersions are prepared byincorporating the various sterilized active ingredient into a sterilevehicle which contains the basic dispersion medium and the requiredother ingredients from those enumerated above. In the case of sterilepowders for the preparation of sterile injectable solutions, thepreferred methods of preparation are vacuum drying and the freeze dryingtechnique which yield a powder of the active ingredient plus anyadditional desired ingredient from previously sterile-filtered solutionthereof.

The therapeutic compounds of this invention may be administered to amammal alone or in combination with pharmaceutically acceptablecarriers, as noted above, the proportion of which is determined by thesolubility and chemical nature of the compound, chosen route ofadministration and standard pharmaceutical practice.

The dosage of the present therapeutic agents which will be most suitablefor prophylaxis or treatment will vary with the form of administration,the particular compound chosen and the physiological characteristics ofthe particular patient under treatment. Generally, small dosages will beused initially and if necessary, will be increased by small incrementsuntil the optimum effect under the circumstances is reached. Thetherapeutic human dosage, based on physiological studies using rats,will generally be from about 0.01 mg to about 100 mg/kg of body weightper day or from about 0.4 mg to about 10 g or higher although it may beadministered in several different dosage units from once to severaltimes a day. Oral administration requires higher dosages.

We claim:
 1. A method of inhibiting cell proliferation in a patientsuffering from a disorder characterized by such proliferation comprisingadministering to a patient a pharmaceutical composition comprising anEGF and/or PDGF receptor inhibiting effective amount of a compound ofthe formula ##STR80## wherein: Ar II is a substituted or unsubstitutedmono- or bicyclic aryl or heteroaryl ring system of about 5 to about 12atoms and where each monocyclic ring may contain 0 to about 3 heteroatoms, and each bicyclic ring may contain 0 to about 4 hetero atoms orat least one ring is a substituted or unsubstituted saturatedcarbocyclic of about 3 to about 7 atoms where each monocyclic ring maycontain 0 to about 2 hetero atoms and where the hetero atoms areselected from N, O and S provided said hetero atoms are not vicinaloxygen and/or sulfur atoms and where the substituents may be located atany appropriate position of the ring system and are described by R;X is(CHR₁)₀₋₄ or (CHR₁)_(m) --Z--(CHR₁)_(n) : Z is O, NR', S, SO or SO₂ : mand n are 0-3 and m+n=0-3; R substitution besides hydrogen independentlyincludes alkyl, alkenyl, phenyl, aralkyl, aralkenyl, hydroxy,hydroxyalkyl, alkoxy, alkoxyalkyl, aralkoxy, acyloxy, halo, haloalkyl,nitro, amino, mono-and di-alkylamino, arylamino, carboxy, carboxyalkyl,carbalkoxy, carbaralkoxy, carbalkoxyalkyl, carbalkoxyalkenyl,aminoalkoxy, amido, mono- and di-alkylamido and N,N-cycloalkylamido,phenyl, halophenyl, thienyl, halothienyl, pyridyl, 1H-tetrazolyl orbenzoyl; R and R together may also be keto; R₁ and R' are hydrogen oralkyl; or an N-oxide or a pharmaceutically acceptable salt thereof, inadmixture with a pharmaceutically acceptable carrier.
 2. A methodaccording to claim 1 where the compound is described by: ##STR81##wherein Ar II is phenyl, naphthyl, thienyl, cyclohexyl or cyclopentyl;andX is a bond, methyl, ethyl, propyl or (CHR₁)_(m) --Z--(CHR₁)_(n)where Z is O, S, SO, SO₂ or NR', and n and m are 0-1 and n+m is 0 or 1.3. A method according to claim 2 comprising administering to saidpatient a pharmaceutically effective amount of a pharmaceuticalcomposition containing, in admixture with a pharmaceutically acceptablecarrier, a compound, or a pharmaceutically acceptable salt thereof, ofthe formulae: ##STR82##
 4. A method according to claim 3 where saidcompound is described by the formula: where:X is a bond, O, NR', methyl,ethyl or propyl.
 5. A method according to claim 3 where said compound isselected from the formula: ##STR83## where: X is a bond, O, NR', methyl,ethyl or propyl.
 6. A method according to claim 4 where the compoundadministered is selected from:2-phenyl-6,7-dimethylquinoxaline,2-phenyl-6,7-dichloroquinoxaline, 2-phenyl-6,7-dimethoxyquinoxaline,2-phenyl-6,7-dimethoxyquinoxaline-4-N-oxide.2-phenyl-6,7-diethoxyquinoxaline,2-(4-fluorophenyl)-6,7-diethoxyquinoxaline,2-(4-fluorophenyl)-6,7-dimethylquinoxaline,2-(4-fluorophenyl)-6-aminoquinoxaline,2-(4-fluorophenyl)-6-acetamidoquinoxaline,2-(4-methoxyphenyl)-6,7-dimethoxyquinoxaline,2-phenethyl-6,7-diethoxyquinoxaline, 2-phenyl-6,7-dicarboxyquinoxaline,2-(4-methoxyphenyl)-6,7-dimethoxyquinoxaline and2-(4-methoxyphenyl)-6,7-dimethoxyquinoxaline-4-N-oxide.
 7. A methodaccording to claim 5 where the compound administered is selectedfrom:2-(thien-3-yl)-6,7-dimethylquinoxaline,2-(thien-3-yl)-6,7-dimethoxyquinoxaline,2-(thien-3-yl)-6,7-diethoxyquinoxaline,2-(5-chlorothien-2-yl)-6,7-diethoxyquinoxaline,2-(5-chlorothien-2-yl)-6,7-dimethoxyquinoxaline,2-(5-fluorothien-2-yl)-6,7-diethoxyquinoxaline,2-(thien-2-yl)-6,7-diethoxyquinoxaline,2-(thien-2-yl)-6,7-dimethoxyquinoxaline and2-(thien-2-yl)-6,7-dicarboxyquinoxaline.
 8. A pharmaceutical compositionfor inhibiting cell proliferation comprising an EGF and/or PDGF receptorinhibiting effective amount of a compound or a pharmaceuticallyacceptable salt thereof selectedfrom:2-(thien-3-yl)-6,7-dimethylquinoxaline;2-(thien-3-yl)-6,7-dimethoxyquinoxaline;2-(thien-3-yl)-6,7-diethoxyquinoxaline;2-(5-chlorothien-2-yl)-6,7-diethoxyquinoxaline;2-(5-chlorothien-2-yl)-6,7-dimethoxyquinoxaline;2-(5-fluorothien-2-yl)-6,7-diethoxyquinoxaline;2-(thien-2-yl)-6,7-diethoxyquinoxaline;2-(thien-2-yl)-6.7-dimethoxyquinoxaline;2-(thien-2-yl)-6,7-dicarboxyquinoxaline;2-phenyl-6,7-dimethylquinoxaline, 2-phenyl-6,7-dichloroquinoxaline,2-phenyl-6,7-dimethoxyquinoxaline,2-phenyl-6,7-dimethoxyquinoxaline-4-N-oxide,2-phenyl-6,7-diethoxyquinoxaline,2-(4-fluorophenyl)-6,7-diethoxyquinoxaline,2-(4-fluorophenyl)-6,7-dimethylquinoxaline,2-(4-fluorophenyl)-6-aminoquinoxalne,2-(4-fluorophenyl)-6-acetamidoquinoxaline,2-(4-methoxyphenyl)-6,7-dimethoxyquinoxaline,2-phenethyl-6,7-diethoxyquinoxaline, 2-phenyl-6,7-dicarboxyquinoxaline2-(4-methoxyphenyl)-6,7-dimethoxyquinoxaline and2-(4-methoxyphenyl)-6,7-dimethoxyquinoxaline4-N-oxide in admixture witha pharmaceutically acceptable carrier.
 9. A compound selectedfrom:2-phenyl-6,7-dimethylquinoxaline, 2-phenyl-6,7-dichloroquinoxaline,. .2-phenyl-6,7-dimethoxyquinoxaline,2-phenyl-6,7-diethoxyquinoxaline,.!.2-(4-fluorophenyl)-6,7-diethoxyquinoxaline,2-(4-fluorophenyl)-6,7-dimethylquinoxaline,2-(4-fluorophenyl)-6-aminoquinoxaline,2-(4-fluorophenyl)-6-acetamidoquinoxaline, ..2-(4-methoxyphenyl)-6,7-dimethoxyquinoxaline,.!.2-phenethyl-6,7-diethoxyquinoxaline, 2-phenyl-6,7-dicarboxyquinoxaline,. .2-(4-methoxyphenyl)-6,7-dimethoxyquinoxaline,.!. or an N-oxide or apharmaceutically acceptable salt thereof.
 10. A compound selectedfrom:2-(thien-3-yl)quinoxaline, ..2-(thien-3-yl)-6,7-dimethylquinoxaline,2-(thien-3-yl)-6,7,-dimethoxyquinoxaline,2-(thien-3-yl)-6,7,-diethoxyquinoxaline,.!.2-(5-chlorothien-3-yl)-6,7,-diethoxyquinoxaline,2-(5-chlorothien-3-yl)-6,7,-dimethoxyquinoxaline,2-(5-fluorothien-3-yl)-6,7,-diethoxyquinoxaline,2-(thien-2-yl)-6,7,-diethoxyquinoxaline,2-(thien-2-yl)-6,7,-dimethoxyquinoxaline,2-(thien-2-yl)-6,7-dicarboxyquinoxaline or an N-oxide or apharmaceutically acceptable salt thereof.
 11. A compound according toclaim 9 which is 2-phenyl-6,7-dimethylquinoxaline or a pharmaceuticallyacceptable salt thereof.
 12. A compound according to claim 10 which is2-(thien-2-yl)-6,7-diethoxyquinoxaline or a pharmaceutically acceptablesalt thereof.
 13. A compound according to claim 10 which is2-(thien-2-yl)-6,7dimethoxyquinoxaline or a pharmaceutically acceptablesalt thereof.
 14. A compound according to claim 10 which is2-(thien-3-yl)quinoxaline or a pharmaceutically acceptable salt thereof.15. A compound according to claim 9, which is2-(4-fluorophenyl)-6,7-diethoxyquinoxaline or a pharmaceuticallyacceptable salt thereof.
 16. A compound according to claim 9 which is2-(4-fluorophenyl)-6,7-dimethoxyquinoxaline or a pharmaceuticallyacceptable salt thereof.
 17. A compound according to claim 9 which is2-(4-fluorophenyl)-6-acetamidoquinoxaline or a pharmaceuticallyacceptable salt thereof.
 18. A compound according to claim 9 which is2-phenethyl-6,7-diethoxyquinoxaline or a pharmaceutically acceptablesalt thereof.
 19. A compound according to claim 9 which is2-phenyl-6,7-dichloroquinoxaline or a pharmaceutically acceptable saltthereof.
 20. A compound according to claim 10 which is2-(5-fluorothien-2-yl)-6,7-diethoxyquinoxaline or a pharmaceuticallyacceptable salt thereof. ##STR84##